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Pharmaceutical manufacturers’ use of prescription brand-name drugs coupons and 
vouchers to subsidize patients’ cost-sharing obligations such as co-pays has increased. 
The co-pays are used by managed care organizations (MCOs) to give their plan members 
an appreciation of drug costs as well as to offer incentives to use available equivalent 
generic alternatives due to lower co-pays. With higher tiered co-pays for brand-name 
drugs being offset by coupons, little is known about MCO representatives’ perceptions 
about use of co-pay subsidy coupons for brand-name prescription drugs. 
The objective of this study was to assess health plan managers and pharmacy 
benefit managers (PBMs) perceptions on the use of prescription drug co-pay subsidy 
coupons. An online survey instrument was used to collect data. A convenience sample of 
 vii 
834 MCO representatives was selected from the Academy of Managed Care Pharmacy 
(AMCP) membership directory.  A total of 122 surveys were returned of which 105 were 
usable surveys, giving a response rate of 13.7%. A five-point, 11-item Likert scale 
ranging from 1 through 5, (1 = ‘Strong Disagree’ and 5 = ‘Strongly Agree’) was used to 
measure respondents’ perceptions. Some items referred to coupons used to get co-pay 
discounts repeatedly over a year (i.e., long-term use coupons) while some items referred 
to coupons distributed for trial purposes (i.e., short-term use coupons). Of the 105 
respondents, 42 (40%) “agreed,” while 58 (55.2%) “strongly agreed” that co-pay subsidy 
coupons encouraged non-preferred brand-name drugs over preferred brand-name drugs. 
A total of 78 respondents (74.3%) reported that brand-name drug coupons undermined 
tiered formulary structure. Sixty respondents (57.1%) “strongly agreed” that short-term 
use coupons increased plan sponsor’s costs and 72 respondents (68.6%) “agreed” that 
sponsor cost increased with long-term use coupons.  A total of 42 (40%) reported to 
“strongly agree” that short-term use coupons should be eliminated whereas 49 (46.7%) 
respondents reported “strongly agreed” that long-term use coupons should be eliminated. 
In summary, MCO representatives believe that brand-name drug utilization is 
increasing due to prescription drug incentives such as coupons which undermines their 
formulary controls and in turn, increases health care costs. 
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Chapter One: Introduction and Literature Review 
1.1 INTRODUCTION 
Coupons are a widely used promotional tool that consumer goods manufacturers 
use to offer discounts on their products. Recently, some pharmaceutical companies have 
started promoting brand-name drugs using coupon offers. Since the vast majority of 
patients has insurance that covers prescription drugs, these coupon offers usually reduce 
or eliminate the patient’s out-of-pocket costs (co-payments).1 In other words, drug 
manufacturers that distribute drug coupons pay for the patient’s portion of the 
prescription drug payment. Co-payments, commonly known as co-pays, typically are the 
cost sharing component for patients who are enrolled in a prescription drug benefit 
program. The remainder of prescription drug costs is paid by the patients’ health plan or 
health insurance company. 
Insurance companies structure co-payments to enhance patients’ price-sensitivity 
toward brand-name drugs and to stimulate patients to use equivalent alternative therapies 
such as generic drugs. Eliminating or waiving co-pays by using coupons results in 
increased use of brand-name prescriptions drugs.2 Furthermore, an increase in brand-
name drug use disrupts the prescription drug control measures implemented by managed 
care organizations (MCOs) such as health plans and pharmacy benefit managers (PBMs) 
to control prescription drug costs. The purpose of this study is to examine MCOs’ (health 
plans and PBMs) representatives’ perceptions toward co-pay subsidy coupon offers. 
.  
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 The following sections provide an overview of types of coupons used by 
pharmaceutical companies, their distribution channels, redemption mechanisms, and 
description of the terms managed care organizations, plan sponsors, and PBMs. This will 
be followed by a literature review which describes the history of prescription drug 
coupons, how coupons have been increasingly used to provide co-pay subsidies, and the 
controversies resulting from their increasing use. 
1.1.1 Types of Prescription Drug Coupons 
 Prescription drug coupons have been distributed by pharmaceutical companies in 
paper or plastic format. Recently, electronic coupons or vouchers programs have been 
implemented at pharmacies to provide discounts on prescription drugs at the point of sale. 
1.1.1.1 Paper Coupons/Vouchers  
Paper coupons/vouchers are the most commonly used coupon type that are 
distributed through newspapers, magazines, or downloaded from drug companies’ 
websites.3 The advantage of prescription drug paper coupons is that if the pharmacy does 
not accept them, the patients can mail them directly to the manufacturers along with the 
receipt to receive a discount on their drug purchase.  
1.1.1.2 Plastic Cards 
Plastic cards are also called adjudicated debit cards, commonly known as the co-
pay cards or loyalty cards.3  These cards are similar to ATM cards. Most prescription 
drug loyalty programs use an adjudicated debit card. It is generally distributed to the 
patient by physicians along with a prescription for the drug. These co-pay cards need to 
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be activated by calling a toll-free number assigned by the manufacturer prior to drug 
purchase. Once the adjudication process is completed, a plastic card can be used a 
number of times toward refilling prescriptions up to a defined limit set by drug 
companies. The advantage of using a plastic card is that the drug manufacturer can 
collect demographic information of card users. This information provides valuable leads 
in conducting market analyses.4 The Figure 1.1 presents an example of plastic card.  
Figure 1.1 Plastic Card or Adjudicated Debit Card 
 
Source: Edmondson M. Coupons, Vouchers, and Adjudicated-Debit Cards: How Is a Brand Manager to Decide? 
Pharmaceutical Executive. March 8, 2008;28:38-40. 
 
1.1.1.3 Electronic Coupons 
Electronic coupons, also known as evouchers, are applied directly to patients’ co-
pays at the pharmacy counter.  Electronic coupon programs are offered through various 
wholesaler companies. Pharmaceutical companies collaborate with wholesaler companies 
to offer discounts on their prescription drug products. For example, McKesson, a supplier 
of pharmacy management systems, offers eVoucher Rx™ solution through its 
RelayHealth service.5 The eVouchers provide immediate co-pay reduction for different 
brand drugs placed in higher formulary tiers. In order to take advantage of the electronic 
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coupons, the patient has to be enrolled in an evoucher program available at specific 
pharmacies. An advantage of this program is that a paper coupon or a co-pay card is not 
required to be presented by the patient to get the discount. The program automatically 
identifies any type of coupon, co-pay reduction, or incentives offered by pharmaceutical 
companies in the adjudication system.6 Figure 1.2 shows one instance in which eVoucher 
is linked to the adjudication process. The display screen shows initial claims response 
when the prescription for test drug is adjudicated at the pharmacy. A message box 
indicates the amount of discount offered to reduce patient’s co-pay. 
Figure 1.2 Display with eVoucher Information 
 
Source: eVoucherRx. Pacific Pharmacy Computers, Inc. Report 





Most paper coupons and co-pay card offers have to be redeemed by the patients at 
pharmacies. In cases where pharmacies do not accept drug coupons, they can be mailed 
to the drug manufacturer. For paper coupons, the pharmacist must submit claims and 
deduct discounts whereas for co-pay cards, the pharmacy receives immediate payment at 
the point of purchase when the card is swiped.7 Electronic vouchers on the other hand 
directly apply co-pay discounts on specific prescription products, i.e., they directly 
reduce patients’ co-pays. 
 Pharmacies do not collect coupon data. Typically, de-identified coupon data are 
collected by coupon distributing agencies or clearing houses. The administrative costs 
associated with coupon, co-pay card, or electronic vouchers are paid by the 
pharmaceutical companies. Figure 1.3 presents the various distribution sources and the 
redemption process of prescription coupons and co-pay cards. 
  
 6 
Figure 1.3 Distribution and Redemption of Prescription Drug Coupons and Co-pay 
Cards 
 
        Pharmaceutical Company 
 
   
 Newspaper, Magazine, Website           Physician’s office 




    Physician   (obtain/renew prescription) 
 
 
Reports and Data    Pharmacy   Discount or   
         Reimbursement or 
         Rebate 
       
     
     
             Distributer or Clearing House 
     
Source: Adapted from: Smith SJ, Buta P. Clipping Coupons. Pharmaceutical Executive. April 1, 2004;24(4):86-92 
1.1.3 MCOs and Plan Sponsors 
In the United States, the majority of Americans are enrolled in some form of 
managed care organization (MCO). MCOs include health plans, PBMs, and insurance 
plans. Health plans are a specific type of MCOs that either finance or provide medical 
care to its enrolled members. Medical care is usually provided through their own facilities 
and staff or indirectly through contracted health care providers such as physicians, 
hospitals, and pharmacies.8 In order to provide prescription drug coverage to their 
members, MCOs share drug costs between plan sponsors and patients. Employers, 
unions, trust funds, or government agencies that provide health insurance are called plan 
sponsors. 
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Plan sponsors usually pay a fixed premium (i.e., a predetermined amount for drug 
insurance coverage for its members or employees) whereas the members pay a portion of 
drug costs through deductibles, co-payments, or co-insurance. Deductibles and co-
payments are fixed-dollar amounts paid by members toward prescription drug costs. A 
deductible is an amount paid by members (100% of the initial portion) before the 
insurance coverage takes over whereas a co-payment is flat rate paid by members 
regardless of total costs. Co-insurance is a percentage of prescription drug cost paid by 
the members.  
1.1.4 Benefit Designs and PBMs 
Employers or plan sponsors contract with third party administrators such as health 
maintenance organizations (HMOs) or preferred provider organizations (PPOs) to 
administer the benefit plans. These entities usually employ benefit designs that are used 
to determine the level of payment.9 PBMs manage the prescription drug benefit portion of 
the plan.  
Benefit design for prescription drugs provides members information about 
alternatives to expensive drugs. It also gives incentives to their members to choose 
equivalent alternatives over high cost prescription drugs. In addition, it includes how cost 
of the drug will be paid, type of benefit such as co-payments or co-insurance, and amount 
of patient cost sharing responsibilities. The benefit designs include special benefit 
requirements such as a drug formulary, the formulary tier structure, prior authorizations 
(physician applied pre-approval for non-covered prescription drugs), mandatory mail-
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order, and other prescription drug restrictions.  As discussed above, plan sponsors pay the 
health insurance costs of patients enrolled in health plans. Prescription drug coupons 
offered by pharmaceutical companies are used only for patients covered by private payers 
such as employers, commercial insurers, and self funded plans. Patients covered by 
public payers such as Medicare and Medicaid are not eligible  to use such coupon 
offers.10-11 Only patients enrolled in private insurance plan such as employer sponsored 
plans or through commercial insurers are eligible to use prescription coupons. As a result, 
private payers have criticized financial incentive programs such as prescription drug 





1.2 LITERATURE REVIEW 
This section will cover the history of prescription drug coupons and the recent 
advancement of pharmaceutical companies in using coupons, vouchers, and co-pay cards 
(also known as loyalty card programs) for co-pay subsidies.  In addition, this review will 
describe the controversies of brand-name prescription drug coupons. 
1.2.1 History of Prescription Drug Coupons and Co-pay Cards 
The history of drug coupons dates back to 1894, when a druggist named Asa 
Candler created coupons for Coca Cola®. At that time, it was used as a patent drug 
product having tonic and nerve stimulant properties.12 Over the past century, coupons 
were extensively used for marketing consumer packaged goods; however, the earliest use 
of pharmaceutical coupons started in early 1980s.13 
The first use of coupons for prescription drugs was initiated by Boots 
Pharmaceuticals in 1981. Boots Pharmaceuticals started promoting its generic ibuprofen 
called Rufen® using a $1.50 rebate coupon. A similar coupon rebate program was used by 
the drug company Zenith for its drug tolazamide in 1986.14  Pharmaceutical coupons in 
the early 1980s were mainly used for promoting generic prescription drug products. A 
birth control pill called N.E.E 1/35m was promoted by Lexis laboratories using rebate 
discounts.15 The active ingredients of N.E.E 1/35m were ethinyl estradiol and 
norethindrone. The advertisements for N.E.E 1/35m were strategically placed in women’s 
magazines such as Ms. Magazine, Cosmopolitan, Mademoiselle, Glamour, Shape, 
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Rolling Stone, and Self. Lexis offered rebate checks of $10 and $20 for six-month and 
twelve-month supplies. 
In the 1990s, chain pharmacies started promoting prescription drugs using 
coupons. Thrift Drug’s mail-order unit, Express Pharmacy Services, mailed its customers 
free co-pay discount coupons for the prescription drug Tagamet®.16 The generic version 
of Tagamet® is cimetidine (see Figure 1.4). This coupon was part of a promotional 
campaign used to motivate consumers to use Tagamet® instead of Zantac® (ranitidine). 
According to an article by Spaulding and Joseph, the Tagamet® coupon was a way of 
attracting consumers by offering free co-payment and directing them to physicians for 
drug substitution.16  













Source : Spaulding CD, Joseph JW. Is Rx Couponing a Viable Direct-marketing Technique? American Pharmacy 
(USA). January 1992;NS32(1):67-71. 
 
Loyalty cards were first introduced in the early 1990s by Marion Merrell Dow for 
the drug Cardizem® (diltiazem). The drug promotion campaign was known as the 
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Cardizem Medication Plus Program.17 The loyalty card entitled patients to free 
prescriptions after a certain usage level. For example, existing card holders’ refill records 
were maintained by pharmacies and after purchases of 540 tablets or more, patients could 
receive a free supply of 90 tablets. In addition, for new patients, prescribing physicians 
could provide an information package and voucher for a free 21-tablet supply of 60, 90, 
and 120 mg strengths. This program reimbursed pharmacists for filling the introductory 
prescription. The Cardizem card program was an attempt by Marion Merrell Dow to 
protect itself from future generic competition after losing its patent exclusivity. 
 Similar coupon programs were used for promoting brand-name drugs 
approaching patent expiration. For example, Schering Plough offered coupons for its 
anti-histaminic drug Claritin® (loratidine) in 2002. The drug manufacturer Novartis 
introduced $5 discount coupons for Zocor® (simvastatin).18 Both drugs were nearing their 
patent expiration when coupons were introduced. Coupons were also used for launching 
new drug products in parallel to promoting existing products. Schering Plough launched 
Clarinex® (desloratidine) in 2002 using a seven-day free trial coupon which could be 
downloaded from the company website.19 In a similar program, Eli Lilly offered a free 
one-month supply of Prozac Weekly® using trial coupons while promoting its anti-
depressant drug Prozac®.20   
1.2.2 Co-pay Cards and Internet Offers 
More recently, drug companies have ventured into another marketing strategy that 
involves subsidizing co-payments on prescription drugs. Co-payments are out-of-pocket 
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costs incurred by insured patients on prescription drugs. Drug companies are offering 
coupons, vouchers, or co-pay cards (also known as loyalty cards) to waive co-payments 
partly or completely on prescription drugs. Table 1.1 shows some of the discounts offered 
by leading pharmaceutical companies for their brand-name prescription drugs in 2009.21 
Many of these discount offers were available on drug companies’ websites.  
Table 1.1 Brand-Name Drugs, Drug Manufacturer, and Co-Pay Description of the 




Drug Manufacturer Co-Pay Description*  
Lipitor®  
(atorvastatin calcium) 
Pfizer Co-pay card with $10 to $15 in 
discount for each refill 
Humira® 
(adalimumab) 
Abbott Laboratories Co-pay card with $5 as 
maximum co-payment 
throughout the year 
Enbrel® 
(etanercept) 
Amgen and Wyeth Co-pay card with no co-
payments for first six months 
and $10 co-pay afterwards. 
Nexium®  
(esomeprazole magnesium) 
Astra Zeneca Co-pay card (The Purple 
Plus™ saving card) entitles 
patient with co-pay of ≥ $25 to 
pay a flat $ 25 co-payment. 
Lunesta® 
(eszopiclone) 
Sepracor Co-pay card offering no co-
payments for first twelve 
months for patients with co-
pay of ≥ $50 on prescription 
drug 
AmbienCR® (zolpidem tartrate 
extended release) 
Sanofi - Aventis Co-pay card with $20 as 
discount for up to first 5 refills 
* the amount of discount in dollar value  using co-pay cards used toward co-payments in a year 





Weppner et al. gave a detailed account of direct-to-consumer offers for free and 
discounted prescription medicines on the internet.22 The author identified the 50 most 
prescribed brand-name prescription medications in 2007. Forty-six (92%) out of the 50 
brand-name prescription medications had a manufacturer-sponsored website. Thirty 
brand-name medications (60%) had one or more prescription voucher offers for free 
samples or discounted medications on their websites. In total, there were 35 individual 
offers; 24 (69%) were for prescription drug discounts and 11 (31%) were vouchers for 
free samples.  
Marketers have emphasized several advantages of using internet coupons over 
traditional pre-printed ones. Online coupons have lower or no distribution cost and it is 
easier to collect product usage information using bar codes printed on coupons.23 
1.2.3 Controversies of Prescription Drug Coupons 
Health care costs, including pharmaceutical costs have continued to escalate for 
health insurance plans and pharmacy benefit managers.  One method used by these 
managed organizations to control or contain the rising pharmaceutical costs is to pass 
some of the costs on to patients. Patient cost-sharing is usually in the form of deductibles, 
co-payments, or co-insurance costs.24  Patient cost-sharing methods are prevalent for 
medical services such as physician office visits, hospitalizations, and a variety of out-
patient procedures. Prescription drugs are no exception.  Most patients today who have 
health insurance or are covered by a managed care organization, which also provides 
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coverage for pharmaceuticals, have to pay a co-payment or co-insurance for prescription 
drugs. 
Health insurers, plans, and pharmacy benefit managers have implemented a 
variety of tiered co-payment benefits for prescription drugs. These co-payment or co-
insurance costs are the patient’s share of the prescription drug’s costs. These are 
commonly referred to as “out-of-pocket cost” for the patient.25 Co-payments are fixed-
dollar amounts per prescription drug dispensed.  In a 2010 survey of 372 employer 
commercial plans, 67% of the employer plans used fixed co-payments for prescription 
drugs.26 Co-payments may range from $1.00 per drug for public assistance programs such 
as Medicaid to over $100.00 for specialty drugs for self-funded employer or commercial 
third-party drug plans. 
Another form of patient cost sharing is when the patient pays a percentage of the 
drug cost. This is referred to as co-insurance.  Based on the 2010-2011 Prescription Drug 
Benefit Cost and Plan Design Report sponsored by Takeda, the median co-insurance rate 
for generic drugs was 10.0% of the product cost, whereas for managed care 
organizations’ preferred brand-name drugs, the median co-insurance cost was 25.0%.27 In 
other words, the patient pays 25% of the total drug costs for preferred brand-name 
pharmaceuticals. The patient’s co-insurance cost is subject to change due to prescription 
drug cost inflation. However, co-payment costs often vary by drug type or the tiered 
category of drugs. 
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The number of co-payment tiers varies by plan; some plans only have one tier 
while others may have five different tiers or categories of drugs.28  For commercial plans, 
three tiers are the most common; these are generic drugs, preferred brand-name drugs 
(drugs listed on the firm’s formulary) and non-preferred brand-name drugs.  Normally, 
the lowest patient cost sharing or co-payment cost is for generic drugs; the reason is that 
generic drugs usually have the lowest drug ingredient cost for the health plan or PBM and 
these organizations want to provide an incentive for patients to use cheaper generic drugs.  
Preferred brand-name drugs usually have next highest co-payment costs. “Preferred 
drugs” are pharmaceutical products which have been approved by the plan and listed on 
the health care plan’s or PBM’s formulary. The next highest co-payment costs are for 
those drugs not listed on the plan’s formulary and thus are referred to as non-preferred 
brand-name drug products. Non-formulary drugs are drugs not included on plan’s drug 
list. Non-formulary brand-name drugs usually have a higher cost and thus are not 
preferred by the health plans or PBMs. The prescriber can request a non-formulary drug 
to be given to the patient, but the prescriber must provide sufficient reasoning that the 
patient requires the drug product; i.e., the prescriber must get prior authorization for the 
non-formulary drug.29 
Table 1.2 presents common tiered plan designs. Higher tier groups are non-
preferred drugs (not included in plan’s preferred list), specialty drugs (drugs 
manufactured through biologic processes to treat chronic, complex, or life-threatening 
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diseases), and lifestyle drugs (drugs that are not medically necessary but improve quality 
of life).30 
Prescription drug coupons are offered on brand-name drugs used to treat 
conditions such as asthma, heartburn, allergy, depression, and hypercholesterolaemia.31 
Recently, coupons have been offered for lifestyle drugs such as those used to treat 
erectile dysfunction, weight-loss, insomnia, birth control, and some skin conditions like 
alopecia.32 These drugs are placed in higher tier groups (i.e., non-preferred brands). 
Because coupons or co-pay cards are used for non-preferred drugs, they subsidize or 
waive higher co-payments. This provides a financial incentive for patients to use non-
preferred brand-name drugs over generic drugs. Table 1.3 presents the average retail co-
payments in 2010 by drug categories for all U.S. employers. 
Table 1.2 Common Tier Plan Designs 
Tier designs Two-tier Three-tier Four-tier Five or more 
tier 
First Tier Generics Generics Generics Generics 
 
Second Tier Brand Preferred brand Preferred brand Preferred brand 
 






Fourth tier   Specialty Specialty 
Fifth or more    Lifestyle 
Source: 2010-2011 Prescription Drug Benefit Cost and Plan Design Report, Sponsored by Takeda Pharmaceuticals 




Table 1.3 Average Retail Prescription Co-payments by Drug Category for All 
Employers (2010) 
Drug Category  Average Copayment (in $) 
Generics   9.57 
Preferred brands 26.31 
Non-preferred brands 46.19 
Brand drugs (Preferred & Non-preferred) 35.92 
Lifestyle 40.47 
Specialty 61.01 
Source: 2010-2011 Prescription Drug Benefit Cost and Plan Design Report, Sponsored by Takeda Pharmaceuticals 
North America, Inc., written by Pharmacy Benefit Management Institute, Scottsdale, AZ. 2010, p.21 
 
The increasing use of co-pay subsidy coupons, vouchers, or cards for promoting 
brand-name prescription drugs has been criticized by MCOs and PBMs. They complain 
that coupons circumvent prescription co-payments which leads to higher brand-name 
drug utilization.33 As more patients use co-pay subsidy coupons for brand-name drugs, 
insurers pay higher ingredient costs.  This may undermine the formulary structure and 
leads to higher brand-name drug utilization. Furthermore, research on prescription drug 
coupons has shown that the presence of coupons is associated with favorable consumer 
attitudes toward the advertisement and the brand.34 In addition, coupons increase the 
likelihood of drug inquiry intention. The increasing use of co-pay subsidy coupons has 
led to growing concern among MCOs such as plans, PBMs, and insurers.35  
1.2.4 Pharmaceutical Companies’ Perspective on Co-pay Subsidy Coupons 
Pharmaceutical companies claim that the use of prescription drug coupons is a 
way to connect directly to consumers.36 They consider delivering coupons or vouchers 
for prescription drugs more economical than delivering samples to physicians.37 The 
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marketing costs for sampling in the U.S. amounts for over $18 billion.38 These include 
costs of using sales representatives, maintaining drug inventories at physicians’ offices, 
and wastage incurred due to drug product expirations.39 Coupons help reduce these 
expenses to drug manufacturers. Another advantage of prescription coupon programs is 
the increased patient affordability for brand-name prescription drugs due to lower co-
payments.40 Furthermore, pharmaceutical companies claim that patients enrolled in 
voucher programs show higher adherence and persistence rates.41  
1.2.5 Strategies to Counteract Coupons 
As mentioned earlier to control the increasing prescription drug costs, managed 
care organizations have implemented strategies that include increasing the difference in 
cost sharing amounts between generics and non-preferred drugs, using stricter formulary 
controls, applying limits on quantity dispensing, requiring prior authorizations, and using 
step therapy approaches that involve starting with the most cost-effective drugs (generics) 
and then progressing to more costly therapy.42-43 Recently, Blue Cross and Blue Shield 
(BCBS) of Michigan launched pilot program that used coupons to waive co-payments on 
generic drugs. This led to a 10% of plan members switching from brand-name drugs to 
generic drugs.44 Critics of co-pay subsidy coupons believe that using similar strategies 
will help counteract brand-name prescription drug coupons.45 
1.2.6 Summary of Literature Review 
Dollar-off coupons and free-sample vouchers were used for promoting generic 
drugs as well as brand-name drugs in the early 1980s. However, these accounted for a 
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very small portion of overall marketing efforts. During this time, the MCO plans covered 
prescription drugs using one common co-pay (i.e., a flat rate of $2 or $5 irrespective of 
whether it was a generic or a brand-name drug).46 With increasing prescription drug 
costs, many managed care plans in the mid-1980s started offering benefit designs with 
tiered co-pay structures. The benefit designs provide incentives to plan member to use 
available generic drugs. The difference in generic and brand-name drugs copayments 
affects brand-name drug utilization which, in turn, results in pharmaceutical companies 
introducing brand drug promotions using co-pay subsidies. Co-pay subsidy coupons are 
widely offered for brand-name drugs with generic alternatives, competing drugs in 
similar therapeutic categories, and newly introduced brand drugs.47 Many of these co-pay 
subsidy coupons are used for drugs used in chronic therapies, life-style drugs, and 
specialty drugs that require patients’ on private insurance to pay higher co-payments.48 
Waived co-payments on such drugs may result in cost-shifting from patients to MCOs. 
This has led to criticism of brand-name drug coupon offers by some consumer groups and 
policy makers.49  
 The purpose of this study is to determine the perceptions of representatives from 
different MCOs such as health plans and PBMs toward co-pay subsidy prescription drug 
coupons.  This study determines if PBMs and health plan providers monitor increases in 
prescription drug coupons and additional costs incurred to their organization due to 
coupons. In addition, this study finds out if MCO representatives have discussions on 
ways to counteract coupons.  Furthermore, this study will determine if health plans and 
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PBMs representatives believe that co-pay subsidy coupons increase both primary 
adherence and persistence. Previous studies have shown that higher co-payments affect 
both the rate at which new prescriptions are filled (primary adherence) as well as rate of 
refills (persistence).50-51 
The information gathered from this survey will provide baseline information to 
help improve communications between pharmaceutical companies and MCOs. 
1.2.7 Objectives 
The overall purpose of this study was to assess the perceptions of Managed Care 
Organization (MCO) representatives regarding the use of co-pay subsidy coupons for 
prescription drugs. For this study, a web-based survey was developed and implemented to 
assess perceptions of health plan managers and PBM representatives. These perception 
scores (dependent variable) were compared by the predominant managed care 
organization, the position in the organization, pharmacy licensure, and number of 
beneficiaries enrolled (independent variables). 
The specific study objectives were to compare health plan/PBM representatives’ 
perceptions regarding whether: 
1. Use of co-pay subsidy coupons encourages utilization of non-preferred brand-
name drugs instead of preferred brand-name drugs by the predominant managed 
care organization, the position in the organization, pharmacy licensure, and 
number of beneficiaries enrolled ; 
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2. Use of co-pay subsidy coupons increases drug costs to plan sponsor by the 
predominant managed care organization, the position in the organization, 
pharmacy licensure, and number of beneficiaries enrolled; 
3. Use of co-pay subsidy coupons improves patient adherence and persistence by the 
predominant managed care organization, the position in the organization, 
pharmacy licensure, and number of beneficiaries enrolled; and 
4. Co-pay subsidy coupons should be eliminated by the predominant managed care 
organization, the position in the organization, pharmacy licensure, and number of 
beneficiaries enrolled. 
All variables used in the study were derived from the items on the survey 
questionnaire. Objectives 2 and 4 measured MCO representatives’ perception on both 
short-term and long-term use co-pay subsidy coupons. The short-term use coupons were 
defined as co-pay cards used for trial offers with usage limit as a requirement by 
manufacturers. For example, co-pay card used for dermatology drugs may have a 
discount limit of up to three uses. Long-term use coupons were defined as co-pay cards 
that could be used repeatedly for a year, (for example; co-pay card for cholesterol 
lowering drugs.) Objective 3 measured perception of MCO representatives toward co-pay 
coupons improving both primary adherence and persistence. 
1.2.8 Hypotheses 
Based on the study objectives, the hypotheses for the study were as follows: 
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H01: There is no difference in the mean perception score of health plan/PBM 
representatives toward whether co-pay subsidy coupons encourage patients to use non-
preferred brand-name drugs instead of preferred brand-name drugs by the predominant 
managed care organization, the position in the organization, pharmacy licensure, and 
number of beneficiaries enrolled. 
H02: There is no difference in the mean perception score of health plan/PBM 
representatives regarding whether short-term use co-pay subsidy coupons increases drug 
costs to plan sponsor by the predominant managed care organization, the position in the 
organization, pharmacy licensure, and number of beneficiaries enrolled. 
H03: There is no difference in the mean perception score of health plan/PBM 
representatives regarding whether long-term use co-pay subsidy coupons increases drug 
costs to plan sponsor by the predominant managed care organization, the position in the 
organization, pharmacy licensure, and number of beneficiaries enrolled 
H04: There is no difference in the mean perception of health plan/PBM representatives in 
regard to co-pay subsidy coupons improving likelihood of first prescription being filled 
by the predominant managed organization, the position in the organization, pharmacy 
licensure, and number of beneficiaries enrolled. 
H05: There is no difference in the mean perception of health plan/PBM representatives in 
regard to co-pay subsidy coupons improving likelihood of prescription refill by the 
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predominant managed organization, the position in the organization, pharmacy licensure, 
and number of beneficiaries enrolled. 
H06: There is no difference in the mean perception of health plan /PBM representatives 
toward short-term use co-pay subsidy coupon elimination by the predominant managed 
care organization, the position in the organization, pharmacy licensure, and number of 
beneficiaries enrolled. 
H07: There is no difference in the mean perception of health plan /PBM representatives 
toward long-term use co-pay subsidy coupon elimination by the predominant managed 




Chapter Two: Methodology  
This chapter describes the instrument, instrument development, study 
respondents, procedures used for survey administration, data collection, and analyses. 
The study was divided into two phases. The first phase involved development of the 
questionnaire, completion of IRB approval, selection of eligible survey respondents, and 
pretest of the questionnaire. The second phase involved administration of the survey, data 
collection, and data analysis. 
2.1 PHASE ONE 
2.1.1 Survey Instrument 
A short survey questionnaire consisting of 28 items was designed for this study 
(see Appendix I). The survey questionnaire was separated into three sections and 
included closed-ended, open-ended, and partially closed-ended questions.  
The closed-ended questions comprised of both ordered and unordered response 
choices. Closed-ended ordered responses were used to provide an entire range of possible 
answers (i.e., gradation of a single concept).52 The respondents choose their answer from 
the most appropriate scale. An example of closed-ended ordered response choices is 
‘strongly disagree’ to ‘strongly agree’. In this questionnaire, items used to measure 
perceptions of ‘health Plan/PBM representatives toward co-pay subsidy coupons’ (all 
items in question 8), and ‘organization’s total enrollment figure’ (question 15) were 
examples of closed-ended questions with ordered response choices. 
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The closed-ended unordered responses do not provide a range or continuum.53 
The responses are a list of answer choices without a scale. An example of closed-ended 
unordered responses is choices that require ranking. In this study questionnaire, 
‘marketing approaches for distributing prescription drug co-pay subsidy coupons’ 
(question 2) was an example of closed-ended question with unordered response type. 
This item asked the respondents to rank the most widely used options using numbers 1 
through 3. The partially closed-ended unordered responses provide a list of answer 
choices along with an option for the survey respondents to write his/her own answer 
choice. An example of a partially closed-ended unordered question was ‘ways in which 
co-pay subsidy coupons could be discouraged’ (question 11). In this question, the answer 
choice ‘other’ (please specify) gave respondents the option to create their own separate 
response.  
Open-ended questions do not provide any response choices. The respondents have 
to formulate their answers; hence, they are considered difficult and may have several 
drawbacks. However, open-ended questions are used when researchers are interested in 
exploring a new topic, or when it is difficult to formulate response choices, or when it is 
necessary to estimate a certain number.54 In this questionnaire, an open-ended question 






The first section consisted of closed-ended questions. The closed-ended questions 
were used to collect the following information from the respondents: 
1. Awareness about use of co-pay subsidy coupons (question 1);  
2. Marketing approaches in distribution of co-pay subsidy coupons (question 2);  
3. Belief regarding whether use of co-pay subsidy coupons had increased, decreased 
or stayed about the same in the previous year (question 3); 
4. Opinion on the top 20 brand-name drugs that used co-pay subsidy coupons 
(question 4); 
5. Whether respondent’s organization monitored coupon use (questions 5 and 6); 
and  
6. Whether respondent’s organization monitored organizational costs due to co-pay 
subsidy coupons (question 7). 
The closed-ended question contained responses such as ‘yes’, ‘no’, and ‘don’t know’. 
Section Two 
The second section of the survey questionnaire comprised of an open-ended 
question, several closed-ended and partially closed-ended questions. The closed-ended 
questions with ordered responses are used to measure perceptions of respondents (all 
items in question 8). This question included 14 items.  Each item consisted of a statement 
and a five-point scale called the Likert scale assigned to measure response on each of the 
statement. The scale for the items ranged from ‘strongly disagree’ to ‘strongly agree’. 
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The respondents were asked to choose the most appropriate answer using this scale. The 
items measured respondents’ perceptions toward impact of co-pay subsidy coupon on 
brand-name drugs (items 8a to 8g), patient adherence (items 8k, 8l), whether co-pay 
subsidy coupon undermined tiered formulary structure (item 8h), increased drug costs to 
plan sponsor (item 8i, 8j), and needed elimination (item 8m, 8n). Some items referred to 
short-term and long-term use co-pay subsidy coupons. 
In the open-ended (question 9), all respondents were asked to estimate the ‘percentage 
increase in utilization of non-preferred brand-name drug in past year’. Question 10 
comprised of a closed-ended question on whether the respondent’s ‘organization had 
discussion on ways in which co-pay coupon use could be discouraged’. The response 
scale used for this question was ‘yes’, ‘no’, and ‘don’t know’.  Question 11 comprised of 
a closed-ended question that asked the respondents to choose the ways in which co-pay 
subsidy coupons were discouraged. The response choices included ‘increase difference in 
cost sharing between generics and non-formulary drugs’, ‘use a step therapy approach 
(defined as coverage of second-line therapy after trial with first-line therapy)’, ‘use 
adherence rewards for generics’, ‘don’t know’ and ‘other’. 
Section Three 
The final section of the questionnaire asked respondents to provide information 
about their work setting. The variables included predominant managed care organization 
(question 12), pharmacy licensure (question 13), respondents’ position in the organization 
(question 14), and number of beneficiaries enrolled (question 15). The variable 
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‘predominant managed care organization’ included categories of ‘health plan’, 
‘pharmacy benefits manager’ (PBM), and ‘other’. The variable ‘pharmacy licensure’ was 
measured using a respondent’s answer to the question ‘Are you a licensed pharmacist?’. 
The response scale was ‘yes’ and ‘no’. The variable ‘position within the organization’ 
included five categories of ‘executive officer’ (president/vice president), ‘program 
manager’ (clinical, pharmacy), ‘director’ (clinical operations, formulary, pharmacy), 
‘pharmacist’ (staff, senior), and ‘other’. The variable ‘number of beneficiaries’ included 
five categories from ‘less than 1,000,000 lives’, ‘1,000,000 – 4,999,999 lives’, ‘5,000,000 
– 9,999,999 lives’, ‘10 million lives or more’ and ‘don’t know’. Question 16 of the 
questionnaire comprised of blank space for respondents to fill in additional comments or 
concerns. 
2.1.2 Institutional Review Board Approval 
Approval was obtained from the University of Texas at Austin Institutional 
Review Board (IRB). This study was in compliance with the policies and procedures 
required for any research with human subjects. The study (IRB Protocol # 2011-03-0048) 
was approved under the exempt category on March 21, 2011. 
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2.1.3 Sample Selection 
The sample of respondents was selected from the Academy of Managed Care 
Pharmacy (AMCP) membership directory for the year 2010-2011. AMCP is a national 
professional association of pharmacists and health care professionals with nearly 6,000 
members. AMCP members consisted of wide diversity of individuals such as university 
enrolled pharmacy students, academics, working executives belonging to the 
pharmaceutical industry, health plan employees, PBMs employees, and individuals 
working in other healthcare organizations. The directory comprised of alphabetical 
listings of AMCP members’ names starting with last name first, position/title, name of 
the work organization, contact information that included organization address, telephone 
number, and email address. The subjects for this study were selected based on: (1) their 
employment in a MCO (i.e., a health plan or a PBM); (2) organization tax status (only 
non-government organizations were selected as prescription drug coupons are disallowed 
in government sponsored programs such as Medicare, Medicaid or state plans); and (3) 
their position within the selected organization. The following table summarizes selection 




Table 2.1 Summary of MCO Representatives’ Selection Based on their Position in 
the Organization. 
Type of MCO 
 


























Humana Health Plans 
Clinical Pharmacist  
Senior Clinical Pharmacist  
Staff Clinical Pharmacist 
 
Pharmacy Program Manager 
Clinical Program Manager 
Formulary Manager 
 
Director of Pharmacy  
Director of Clinical operations 
Formulary Director 
 





President, Clinical operations 
President, Formulary management 
President, Pharmacy 
Prescription Solutions 
MedImpact Healthcare Systems 






a PBM – Pharmacy Benefit Managers, BC/BS – Blue Cross Blue Shield 
bSome examples of non-government  health plan and PBMs selected based on selection criteria 
cHealth Plan and PBM representatives selected based on their title/position in organization 
 
The subjects were selected using convenience sampling which is a non-
probability sampling technique. The sample was selected from the AMCP directory, a 
publically available membership list. The researchers selected the subjects alphabetically 
from this list. All AMCP members that met the inclusion criteria were selected. 
   A total of 834 members were selected from the AMCP directory.  
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2.1.4 Pretest 
To pretest the questionnaire, a survey link was sent to small sample of four MCO 
representatives to assess the clarity and completeness of the questionnaire. In addition to 
getting responses, the primary purpose was to identify unclear or confusing items and to 
record the time needed for completion of the survey. 
Based on the pretest, some of the items on the survey instrument were re-worded. 
For example, in the pretest questionnaire item, ‘Do you believe that in the past year the 
number of co-pay subsidy coupons offered by pharmaceutical manufacturers have 
increased’ was changed to ‘Do you believe that in the past year the number of co-pay 
subsidy coupons offered by pharmaceutical manufacturers has increased, decreased, or 
stayed about the same as in previous year’. 
Question 8, (item i) ‘co-pay subsidy coupons increase drug costs to managed care firms’ 
was changed to ‘co-pay subsidy coupons increase drug costs to plan sponsors’. Items 
referring to short-term use and long-term use co-pay subsidy coupons were added in the 
survey instrument. For example items 8d, 8e, 8f, 8g, 8i, 8j, 8m, and 8n were included in 
the final survey instrument. 
The item ‘please estimate the increase in number of prescription drug co-pay subsidy 
coupons since last year’ was deleted as pretest respondents considered it to be a difficult 
question. From Question 11, ‘please specify ways in which the use of co-pay subsidy 
coupons could be discouraged’ the answer choice ‘eliminate coupons completely’ was 
deleted as the pretest respondents noted that it was beyond health plan/PBMs control to 
eliminate the use of coupon offers by their plan members. Various suggestions were 
integrated into the final survey instrument (See Appendix I). Respondents noted that the 
time to complete the questionnaire was 5 to 7 minutes. 
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2.2 PHASE TWO 
The second phase involved administering the survey to selected subjects. Previous 
studies suggest that there has been a low response rate with MCO representatives.55 Thus, 
the survey was administered to all 834 selected MCO representatives. 
2.2.1 Administration of the Survey 
This questionnaire was uploaded on SurveyMonkey™ which is an online survey 
tool that enables users to create, distribute, and collect results of online surveys. For the 
purpose of this study, a SSL (Secure Socket Layer) encryption plan was used for 
SurveyMonkey™. SSL encryption is in compliance with Health Insurance Portability and 
Accountability Act (HIPAA) regulations. It is mainly used for transferring secured 
private documents.  
According to Dillman (2007), multiple contacts are essential in order to encourage 
high response rate.56 Dillman suggests that there should be four or more contacts with 
respondents. This may include a pre-notice, the survey questionnaire, a Thank 
you/Reminder, and a replacement questionnaire. In addition, Dillman highlights the 
importance of a pre-notice and personalized email. A pre-notice should be sent out before 
sending the survey questionnaire which should include the purpose of the study and the 
upcoming survey questionnaire notification. The pre-notice must be short and succinct as 
email recipients could discard lengthy emails. Similarly, personalized emails could be 
used to increase response rate.57 For this study, an invitation email and two reminder 
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emails were sent. A total of three contacts were made with the email recipients. A pre-
notice was not sent in this survey.   
The first email invitation was sent to the selected subjects in the week of July 12, 
2011 at 12 p.m. (central time) via the researcher’s residential internet connection. The 
email included the purpose of the study, a link to the survey and a brief explanation of 
voluntary participation, respondents’ confidentiality, privacy, and anonymous data 
collection (see Appendix II). It also restated that clicking on the survey link was 
considered as the consent to participate. In addition, the invitation email included contact 
information of the IRB committee’s chair person and the researchers involved in the 
study. The purpose of including contact information was to answer any queries from the 
respondents pertaining to the study. A signed cover letter with the exact same wordings 
as the email was included as an attachment to the invitation email (see Appendix II). In 
order to avoid disclosure of email addresses to everyone on the list, email was sent as 
blind carbon copy (bcc) to each email recipient.  
The online questionnaire was designed to take no longer than 7 minutes to 
complete. The participants were asked to click on the URL that appeared as: 
https://www.surveymonkey.com/s/RSRTPYT on the email. The data were 
collected online and was password protected. Only the researchers involved in this study 
had access. 
Two follow-up reminder emails were sent to all the eligible respondents between 
12:00 and 12.30 p.m. Central time (see Appendices III and IV). These emails were sent 
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one week (July 18, 2011) and three weeks (August 1, 2011) after the initial invitation 
email. These emails covered all content of the invitation email in addition to thanking 
subjects who had already completed the survey. A signed reminder letter was attached 
with both these emails. 
2.2.2 Data Collection 
The data collection began on July 12, 2011 and ended on August 11, 2011, a one- 
month time period.  
2.2.3 Data Analysis 
All responses were collected on a spreadsheet which was extracted using 
Microsoft Excel®. The Excel® spreadsheet was later imported to the Predictive Analytics 
Software (PASW)® version 18.0 for analysis. The data were cleaned and descriptive 
analysis was performed on all variables.  
2.2.3.1 Descriptive Analysis 
Descriptive analysis (means, standard deviations, frequency distributions) were 
reported for all variables in the instrument. Means were reported for continuous data such 
as ‘perceptions regarding use of co-pay subsidy coupons have impact on brand-drug 
utilization, patient adherence, and costs (all items in question 8), and percentage increase 
in utilization of non-preferred drug since past year (question 9).  
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2.2.3.2 Independent Variables 
Independent variables used were ‘predominant managed care organization’, 
‘pharmacy licensure’, ‘position within the organization’, and ‘number of beneficiaries 
enrolled’.  
The variable ‘predominant managed care organization’ was derived from 
question 12 (see Appendix I) of the survey questionnaire and was worded as ‘Which of 
the following best describes predominant managed organization where you work?’ It is 
defined as subject’s primary work setting (i.e., whether he/she worked for a health plan or 
a pharmacy benefit manager.) The subjects were divided into two groups based on their 
answer choice. The health plan manager group was coded as ‘1’and the PBM group was 
coded as ‘2’. 
The variable ‘pharmacy licensure’ refers to the subject holding licensure to 
practice pharmacy. The variable was obtained from question 13 of the questionnaire 
worded as ‘Are you a licensed pharmacist?’ The subjects were classified into two groups 
licensed pharmacists and others (i.e., subjects not holding pharmacy licensure) and the 
answer choices were coded as ‘1’ and ‘2’ respectively.  
The variable ‘position within the organization’ refers to designation of the subject 
working in a health plan or a PBM setting. This variable was obtained from question 14 
worded as ‘Which of the following best describes your position in the organization where 
you are employed?’ The answer choices of subjects were coded as follows ‘executive 
officer’ = 1, ‘program manager’ = 2, ‘director’ = 3, ‘pharmacist’ = 4, and ‘other’ = 5. 
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The variable ‘number of beneficiaries enrolled’ was defined as total enrollment of 
subject’s organization. This variable was obtained from question number 15 of the survey 
questionnaire. The subjects were asked to choose the approximate total enrollment of 
their organization. Based on their response, they were classified into five groups for data 
analysis: subjects having total enrollment of ‘less than 1,000,000 lives’ coded as 1; 
between ‘1,000,000 to 4,999,999 lives’ coded as 2; enrollment between ‘5,000,000 to 
9,999,999 lives’ coded as 3, ‘greater than or equal to 10 million lives’ coded as 4, and 
don’t know (i.e., subjects unaware of their total organization’s enrollment) coded as 5. 
2.2.2.3 Dependent Variables 
Based on the study objectives, the dependent variables were perception scores of 
Health Plan/PBM representatives. The following table presents the dependent variables 
and the codes used in data analysis 
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Co-pay subsidy coupon use encourages non-preferred 
brand-name drug utilization instead of preferred 
brand-name drugs 
8c  
Strongly Disagree = 1 
 
Disagree = 2 
 
Neutral = 3 
 
Agree = 4 
 
Strongly Agree = 5 
Short-term use co-pay subsidy coupons increase drug 
cost to plan sponsor 
8i 
Long-term use co-pay subsidy coupons increase drug 
cost to plan sponsor 
8j 
Co-pay subsidy coupon use improve likelihood of 
first prescription being filled 
8k 
Co-pay subsidy coupon use improve likelihood of 
refill 
8l 
Short-term use co-pay subsidy coupons should be 
eliminated 
8m 




Perception scores of MCO respondents 
b Codes for Likert scale items. All items were scored using Likert scale. 
 
2.2.3.4 Hypothesis Testing 
All statistical analyses were performed using PASW® version 18. An a priori 
significance level of p < 0.05 was used for all the statistical tests. Table 2.3 summarizes 
the study hypotheses, variables, and statistical tests that were used. 
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Table 2.3 Summary of Hypotheses, Variables, and Statistical Tests 
Hypothesis Dependent Variable 
(DV)a 
Independent Variables (IV)b Statistical Tests  





instead of preferred 
brand-name drugs 
-Predominant Managed 
  Care Organization (IV1) 
-Pharmacy Licensure (IV2) 
-Position (IV3) 
- Number of Beneficiaries 
  Enrolled (IV4) 
 Two sample T-test 
 
Two sample T-test 
One-way ANOVA 
One-way ANOVA 
H02 Short-term use co-pay 
subsidy coupons 






Two sample T-test 
Two sample T-test 
One-way ANOVA 
One-way ANOVA 
H03 Long-term use co-pay 
subsidy coupons 






Two sample T-test 
Two sample T-test 
One-way ANOVA 
One-way ANOVA 
H04 Co-pay subsidy 
coupon use improve 







Two sample T-test 
Two sample T-test 
One-way ANOVA 
One-way ANOVA 
H05 Co-pay subsidy 
coupon use improve 





Two sample T-test 
Two sample T-test 
One-way ANOVA 
One-way ANOVA 
H06 Short-term use co-pay 
subsidy coupons 





Two sample T-test 
Two sample T-test 
One-way ANOVA 
One-way ANOVA 
H07 Long-term use co-pay 
subsidy coupons 





Two sample T-test 
Two sample T-test 
One-way ANOVA 
One-way ANOVA 
aAll dependent variables are continuous, bAll independent variables are categorical 
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Chapter Three: Results 
This chapter will describe the results of the descriptive analysis and the 
hypothesis testing. 
3.1 ANALYSIS OF STUDY PROCEDURE 
A total of 834 invitation emails were sent to the selected MCO representatives, of 
which 60 resulted in delivery failures. Thus, it is assumed that a total sample size of 774 
received the survey.  Four refused to participate; one indicated he/she worked for a 
Medicaid plan; and two respondents were from health plans of Massachusetts (MA) 
hence were not eligible to take the survey.  Thus, these email addresses (bounced, refused 
to participate, and MA / Medicaid health plans) were deleted from the final list of 
members to which the survey was sent. Therefore, a total sample size was 767 was 
considered delivered after reminder emails.  Two reminder emails were sent after the 
invitation email. Fifty-seven (7.43%) responses were received after the first invitation 
email, followed by 41 (5.34%) responses after the second reminder, and 24 (3.12%) 
responses after the third reminder email.  A total of 122 responses were received for a 
response rate of 15.90 % (122/767) after the third email.  Of the 122 survey respondents, 
11 surveys were incomplete and 6 surveys were excluded from analysis based on the 
selection criteria. The excluded survey responses were from three independent health care 
consultants; one specialty pharmacist; one outcomes research manager, and one managed 
service organization (MSO) representative. Therefore, the number of usable responses 
was 105 for a response rate of 13.68 % (105/767). 
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3.2 DESCRIPTIVE ANALYSIS 
3.2.1 Respondents’ Characteristics 
The characteristics of MCO respondents are presented in Table 3.1. Of the 105 
respondents, 79 (75.2%) were health plan employees. A majority of MCO 
representatives, 100 (95.2%), were licensed pharmacists. In terms of current position in 
the organization, 56 (53.3%) were directors, 26 (24.8%) were program managers, 14 
(13.3%) were pharmacists, and 9 (8.6%) were executive officers. A majority of MCO 
respondents, 50 (47.6%), had total enrollment of less than 1 million lives within their 
organization, 19 (18.1%) respondents reported organization enrollment between 
1,000,000 and 4,999,999 whereas 9 (8.6%) respondents reported enrollment between 
4,999,999 and 9,999,999 lives. Twenty five (23.8%) respondents indicated that their 




Table 3.1 Characteristics of Respondents 
Total number of respondents (N) = 105 
aOne respondent did not answer this item 
bMCO – Managed Care Organization, PBM - Pharmacy Benefit Manager 
cExecutive officers include President/Vice-President of Clinical Operations, Formulary or Pharmacy;  
  Program Managers of Clinical Operations and Pharmacy; 
  Director of Clinical Operations, Formulary or Pharmacy; 
  and Senior/Staff Pharmacists of Clinical Operations and Pharmacy 
d






Measure N (%) N (Total)  

















Current Positionc Executive Officer  9 (8.6) 105 
Program Manager  26 (24.8) 






< 1,000,000 lives 50 (47.6) 105 
1,000,000 – 4,999,999 
lives 
19 (18.1) 
5,000,000 – 9,999,999 
lives 
  9 (8.6) 
≥ 10 million lives 25 (23.8) 
Don’t Know   2 (1.9) 
 42 
3.2.2 Perceptions of MCO Representatives about Co-pay Subsidy Coupons 
MCO respondents were asked about their perceptions toward prescription drug 
co-pay subsidy coupons. Table 3.2 presents the items and the descriptive statistics on 
respondents’ perceptions about prescription drug co-pay subsidy coupons (question 8). 
Respondents were asked to rate the 14 items (question 8) using a five-point Likert scale. 
These items were scored 1 through 5 with 1 = ‘Strong Disagree’, 2 = ‘Disagree’, 3 = 
‘Neutral’, 4 = ‘Agree’, and 5 = ‘Strongly Agree’.  
Of the 105 MCO respondents, 54 (51.4%) ‘agreed’ while 31 (29.5%) ‘strongly 
agreed’ that patients are more likely to shift from generic to brand-name drugs when they 
receive co-pay subsidy coupons (item 8a). The mean (± SD) perception score of the 
MCO respondents on this item was 4.01 (± 0.88).  When asked whether co-pay subsidy 
coupons increase utilization of brand-name prescription drugs instead of generic drugs 
(item 8b), 48 (46.2%) ‘agreed’ whereas 51 (49.0%) ‘strongly agreed.’ The mean 
perception score on this item was 4.43 (± 0.62). Of the 105 respondents, a majority 58 
(55.2%) ‘strongly agreed’ while 42 (40.0%) ‘agreed’ that co-pay subsidy coupons 
encouraged patients to use nonpreferred drugs (item 8c). The mean (± SD) perception 
score was 4.48 (± 0.68).  
MCO respondents were asked whether a majority of patients who take advantage 
of short-term use co-pay subsidy coupons become regular users of brand-name drugs 
(item 8d). A large number of MCO respondents 48 (45.7%) ‘agreed’ while 18 (17.1%) 
‘disagreed’, and 25 (23.8%) indicated ‘neutral.’  The mean (± SD) perception score for 
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this item was 3.51 (± 0.95). MCO respondents indicated that a majority of patients who 
take advantage of long-term use co-pay subsidy coupons become regular users of brand-
name drugs (item 8e). Forty-eight (46.2%) respondents ‘agreed’ with this statement 
whereas 41 (39.4%) ‘strongly agreed.’  MCO respondents were asked whether short-term 
co-pay subsidy coupons build brand-loyalty toward brand-name prescription drugs (item 
8f). Forty-seven (45.2%) ‘agreed’, 29 (27.9%) indicated ‘neutral’ while 14 (13.5 %) 
respondents ‘disagreed.’ The mean (± SD) perception score was 3.55 (± 0.91). For the 
item, ‘long-term use co-pay subsidy coupons build brand-loyalty toward brand-name 
prescription drugs (item 8g)’, 54 (51.4%) respondents ‘agreed’ while 37 (35.2%) 
‘strongly agreed.’ The mean (± SD) perception score on this item was 4.17 (± 0.78).  
A majority of MCO representatives 78 (74.3%) ‘agreed’ that co-pay subsidy 
coupons undermined the tiered formulary structure (item 8h). In general, a large 
proportion of MCO representatives 'strongly agreed’ that both short-term use 60 (57.1%) 
and long-term use 72 (68.6%) co-pay subsidy coupons increased costs to plan sponsor 
(item 8i and 8j). The mean (± SD) perception scores on these items were 4.43 (± 0.76) 
and 4.58 (± 0.70) respectively.  
When MCO respondents were asked about their perception toward co-pay subsidy 
coupons improving likelihood that patients will get first prescription filled (item k), there 
were mixed responses. Of the 104 respondents, 12 (11.5%) ‘disagreed’, 40 (38.5%) 
indicated ‘neutral’, 39 (37.5%) ‘agreed’, while 11 (10.6%) ‘strongly agreed.’ The mean 
(± SD) perception score on this item was 3.43 (± 0.90).  For item 8l, ‘Co-pay subsidy 
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coupons improve the likelihood that patients will obtain refill prescriptions’, 20 (19%) 
‘disagreed’, 38 (36.2%) indicated ‘neutral’, 38 (36.2%) ‘agreed’, while only 7 (6.7%) 
‘strongly agreed.’  The mean perception score on item 8l was 3.27 (± 0.91).  
MCO representatives ‘agreed’ that both short-term use and long-term use co-pay 
subsidy coupons should be eliminated (items 8m and 8l). The mean (± SD) perception 
scores on these items were 3.96 (± 1.0); 4.11 (± 1.0) respectively. Forty-two (40.0%) 
‘strongly agreed’ that short-term co-pay subsidy coupons should be eliminated while 49 
(46.7%) ‘strongly agreed’ that long-term co-pay subsidy coupons should be eliminated. 
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aSD – Strongly Disagree, D – Disagree, N – Neutral, A – Agree, SA - Strongly Agree (coded 1 to 5) 
bFrequency with missing responses 
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aSD – Strongly Disagree, D – Disagree, N – Neutral, A – Agree, SA - Strongly Agree (coded 1 to 5) 
b Frequency with missing responses 
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3.2.3 MCO Representatives’ Beliefs Regarding Change in Number of Co-pay 
Subsidy Coupons 
The MCO representatives were asked if they believed the number of co-pay 
subsidy coupons offered by pharmaceutical manufacturer increased, decreased, or stayed 
about the same as compared to previous year. Table 3.3 shows the frequency distribution 
of MCO representatives’ responses about their belief on change in number of co-pay 
subsidy coupons. A total of 91 (86.7%) of the 105 believed that the number of co-pay 
subsidy coupons had increased as compared to the previous year, 13 (12.4%) indicated 
that it had stayed about the same, and 1 (1.0%) believed that it has decreased. 
Table 3.3 Frequency Distribution of MCO Representatives’ Belief Regarding 
Change in Number of Co-pay Subsidy Coupons 
Change in number of co-pay subsidy coupons as 
compared to 2010a 
Nb (%) 
Increased  91 (86.7) 
Decreased 1 (1.0) 
Stayed about the same 13 (12.4) 
a Belief of respondents that in the number of co-pay subsidy coupons offered by pharmaceutical 
manufacturers have changed in past year compared to its previous year 
b Total number of  respondents N=105 
 
3.2.4 Opinion on Brand-name Drugs that Use Coupons for Promotion 
The respondents were asked about their opinion on the number of top 20 brand-
name prescription drugs that use coupons for promotion. Of the 105 respondents, 47 




Table 3.4 Responses to the Item, ‘In Your Opinion, Approximately How Many of 
the Top 20 Brand-Name Prescription Drugs Use Coupon Promotions?’ 
Number of brand-name prescription 
drugs using couponsa 
Nb (%) 
None 0 (0.0) 
1 to 3 9 (8.6) 
4 to 6 21 (20.0) 
7 to 9 16 (15.2) 
10 or more 47 (44.8) 
Don’t know 12 (11.4) 
aRespondents’ opinion on top 20 brand-name prescription drugs that use coupons for promotion 
bTotal number of respondents N=105. 
3.2.5 Monitoring Co-pay Subsidy Coupons by MCO   
MCO representatives were asked to indicate whether his or her organization 
monitored prescription drug coupons, or if their organization contracted other 
organization to monitor prescription drug coupons. Table 3.5 presents the frequency 
distribution of MCO representatives’ coupon monitoring activities for prescription drugs.  
In addition, MCO representatives were asked to indicate if their organization monitored 
costs incurred due to use of prescription drug coupons. These results are also presented in 
Table 3.5.  
Twenty four (22.9%) of the 105 MCO respondents indicated that they monitored 
coupon/vouchers for brand-name prescriptions, while 72 (68.6%) indicated they did not. 
A total of 95 (90.5%) of 105 respondents did not contract with another organization to 
monitor use of coupons for brand-name drugs. A total of 23 respondents (21.9%) 
reported that their organization monitored cost incurred due to coupon/voucher use. 
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Table 3.5 Frequency Distribution of Co-pay Subsidy Coupon Monitoring Activities 
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3.2.6 Approaches for Distributing Prescription Drug Co-pay Subsidy Coupons 
MCO respondents were asked to rank the most widely used marketing approach 
for distributing prescription drug coupons using numbers 1 through 3 with “1” being the 
most widely used marketing approach, “2”  being the second most widely used approach, 
and “3” being the third most widely used marketing approach. There were seven answer 
choices: newspapers; magazine coupons; internet offers; direct mail to consumer; 
pharmacies; physicians; and other (question 2 of the questionnaire). Table 3.6 provides a 
description of widely used marketing approaches in distributing prescription drug co-pay 
subsidy coupons. Sixty-three (60.0%) out of 105 respondents indicated couponing 
through physician offices as the most widely used marketing approach, this was followed 
by internet offers (N=26, 24.8%) and the third most frequent response was  magazine 
coupons (N=29, 27.6%).  In terms of total mentions,  90 (85.7%) respondents indicated 
physicians among the first three widely used marketing options, followed by internet 
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offers 74 (70.5%), magazine coupon 60 (57.1%), pharmacies 38 (36.2%), direct-mail to 
consumer 31 (29.5%), and newspaper 23 (21.9%). 
























Physicians 63 (60.0) 20 (19.0) 7 (6.7) 90 (85.7) 15 (14.3) 105 
(100.0) 




6 (5.7) 25 (23.8) 29 (27.6) 60 (57.1) 45 (42.9) 105 
(100.0) 




1 (1.0) 10 (9.5)   20 (19.6) 31 (29.5) 74 (70.5) 105 
(100.0) 
Newspapers 3 (2.9) 8 (7.6) 12 (11.4) 23 (21.9) 82 (78.1) 105 
(100.0) 
a Indicates total frequency of MCO respondents who ranked the marketing option as 1,2, and 3 
 1 – Most Widely Used; 2 – Second Most Widely Used; 3 – Third Most Widely Used.  
 
3.2.7 Estimate of Percent Increase in Non-preferred Brand-name Drug Utilization  
MCO respondents were asked to estimate the percentage increase in utilization of 
co-pay subsidy coupons. Table 3.7 presents MCO respondents’ estimates. Seventy-nine 
(75.2 %) of the 105 MCO respondents reported “Don’t Know.”   
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Table 3.7 Estimate of Percent Increase in Non-preferred Brand-name Drug 
Utilization 
Estimate on non-preferred brand-name 
drug utilization (in percentage) 
Na(%) 
Don’t Know   79 (75.2) 
  0  1 (1.0) 
  3  2 (1.9) 
  5 5 (4.8) 
  6 1 (1.0) 
10 4 (3.8) 
15 2 (1.9) 
20 1 (1.0) 
25 1 (1.0) 
35 1 (1.0) 
55 1 (1.0) 
150 1 (1.0) 
Total 99 (94.3) 
a Number of respondents = 99 ; System missing = 6 
3.2.8 Ways to Discourage Co-pay Subsidy Coupons 
MCO respondents were asked if during the past year their organization had 
discussion on ways to discourage co-pay subsidy coupons in the past year. Table 3.8 
presents the results. Of the 104 respondents, 69 (66.3 %) reported that their organization 
had discussion on ways to discourage co-pay subsidy coupons in the past year. Four 
respondents reported ‘don’t know’ indicating that they were not aware about their 
organization’s discussions to discourage prescription drug coupon use.  
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Table 3.8 Responses to Item, ‘During the Past Year, Has Your Organization had 
Discussions about Ways in Which Co-pay Subsidy Coupons Could Be 
Discouraged?’ 
Discussions about ways in which co-pay subsidy 
coupons could be discourageda 
    N (%) 
Yes   69 (66.3) 
No   31 (29.8) 
Don’t Know   4   (3.8)  
Total 104 (100.0) 
aMCO respondents opinion on ways in which co-pay subsidy coupons 
 
MCO respondents were asked to specify ways in which co-pay subsidy coupons 
could be discouraged. Table 3.9 presents the results. A total of 98 (93.3%) out of the 105 
respondents answered the question. Since MCO respondents were asked to choose 
multiple responses, there were a total of 196 responses. Eighty-nine respondents (45.4%) 
indicated using step therapy approach, followed by 58 (29.6%) who reported that the 
difference in cost sharing between generics and non-formulary drugs should be increased, 
and 49 (25.0%) indicated using adherence rewards for generic drugs.   
Table 3.9 Discussion on Ways to Discourage Co-pay Subsidy Coupons 
Ways to discourage coupons Responses 
N (%) 
Increase difference in cost sharing between 
generics and non-formulary drugs 
58 (29.6) 
 
Using step therapy approach 89 (45.4) 
Use adherence rewards 49 (25.0) 
Don’t know 0   (0.0)  
Total 196 (100.0) 
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In addition, MCO respondents were given an option to specify ways other than 
the one on the checklist. The following are some of the ways suggested by MCO 
respondents to discourage use of co-pay subsidy coupons:  
1. Health plans should omit coverage for brand-name drugs that are promoted 
using co-pay subsidy coupons; 
2. Use legal contracts with pharmacy networks to ban use of co-pay 
cards/vouchers/coupons for brand-name drugs; 
3. Use co-insurance instead of co-payments on approved prescription drugs; 
4. Health plans should provide incentives to use preferred brand-name drugs to 
their members; 
5. Use mandatory mail-order pharmacy; and  
6. Make a separate tier for drugs that are promoted by co-pay subsidy coupons. 
3.3 HYPOTHESES TESTING 
This study had seven hypotheses. The statistical tests that addressed each 
hypothesis were presented in Table 2.3.  For each hypothesis, a dependent variable 
(perception score) was tested against three independent variables: the predominant 
managed care organization (IV1), the position in the organization (IV2), and number of 
beneficiaries enrolled (IV4). 
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 For each hypothesis, two statistical tests were used: two-sample T-test and two, 
one-way ANOVA. For pharmacy licensure (variable IV3), there was inadequate number 
of respondents without pharmacy licensure to do the hypotheses testing. Hence in the 
following sections will describe three statistical tests (i.e., one two-sample T-test and two, 
one-way ANOVAs) per hypothesis. 
3.3.1 Two-sample T- test  
A two-sample T-test was used to compare the mean perception score of MCO 
respondents’ (dependent variables) by the predominant managed care organization (IV1). 
MCOs were categorized as either a health plan or a PBM.  Table 3.10 provides the 
descriptive statistics (i.e., mean, and standard deviation), the t-statistic (t), degrees of 
freedom (df), and significance level. No statistical significant differences were found for 
the items controlling for type of managed care organization  
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Table 3.10 Two-Sample T-Test Comparison of Mean Perception Score between 
Health Plan and PBM Representatives 
Dependent variables Predominant MCOa df t Sig. 
Health Plan  
(N =  79) 
PBMb   
(N= 26) 
Mean    SD      Mean       SD 
Co-pay subsidy coupon use 
encourages non-preferred 
brand-name drug utilization 




4.49     0.68 
 







Short-term use co-pay 
subsidy coupons increase 
drug cost to plan sponsors* 
 
 
4.38    0.82 
 







Long-term use co-pay 
subsidy coupons increase 
drug cost to plan sponsors* 
 
 
4.54    0.76 
 







Co-pay subsidy coupon use 
improve likelihood of first 
prescription being filled# 
 
 
3.38    0.92 
 







Co-pay subsidy coupon use 
improve likelihood of refill 
 
 
3.22     0.97 
 







Short-term use co-pay 




4.00     1.00 
 







Long-term use co-pay 
subsidy coupons should be 
eliminated 
 
4.13     1.00 
 







Dependent variables were measured on 5-point Likert scale ranging 1 to 5 (1 = ‘Strongly Disagree’ and 5 = 
‘Strongly Agree’) 
aMCO - Managed Care Organization 
bPBM -  Pharmacy Benefit Manager 
SD – Standard Deviation 
*Equal variances not assumed 




Interpretation of Results: 
The following section will present the hypothesis for the variable predominant 
managed care organization and interpretation of the results using two-sample T-tests.  
Hypothesis 1: There is no difference in the mean perception score of Health Plan/PBM 
representatives toward whether co-pay subsidy coupons encourage patients to use non-
preferred brand-name drugs instead of preferred brand-name drugs by the predominant 
managed care organization. 
T-test for Hypothesis 1 
The t-test showed no significant difference in mean perception score between health plan 
(4.49, SD = 0.68) and PBM (4.42, SD = 0.70) representatives (t = 0.457; df = 103; p = 
0.649) on whether co-pay subsidy coupons encouraged non-preferred brand-name drug 
utilization over preferred brand-name drugs. 
Hypothesis 2: There is no difference in the mean perception score of Health Plan/PBM 
representatives regarding whether short-term use co-pay subsidy coupons increase drug 
costs to plan sponsor by the predominant managed care organization. 
T-test for Hypothesis 2 
The T-test showed no significant difference in mean perception score between health plan 
(4.38, SD = 0.82) and PBM (4.58, SD = 0.51) representatives (t = -1.458; df = 70.548;      
p = 0.149) on whether short-term co-pay subsidy coupons increase costs to plan sponsor. 
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Hypothesis 3: There is no difference in the mean perception score of Health Plan/PBM 
representatives regarding whether long-term use co-pay subsidy coupons increase drug 
costs to plan sponsor by the predominant managed care organization.  
T-test for Hypothesis 3 
The T-test showed no significant difference in mean perception score between health plan 
(4.54, SD = 0.76) and PBM (4.69, SD = 0.47) representatives (t = - 1.173; df = 70.285; p 
= 0.245) on whether long-term co-pay subsidy coupons increases costs to plan sponsor. 
Hypothesis 4: There is no difference in the mean perception of Health Plan/PBM 
representatives in regard to co-pay subsidy coupons improving likelihood of first 
prescription being filled by the predominant managed organization. 
T-test for Hypothesis 4 
The T-test showed no significant difference in mean perception score between health plan 
(3.38, SD = 0.92) and PBM (3.58, SD = 0.80) representatives (t = - 0.942; df = 102; p = 
0.348) on whether short-term co-pay subsidy coupons improve likelihood of first 
prescription being filled. 
Hypothesis 5: There is no difference in the mean perception of Health Plan/PBM 
representatives in regard to co-pay subsidy coupons improving likelihood of prescription 
refill by the predominant managed organization. 
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T-test for Hypothesis 5 
The T-test showed no significant difference in mean perception score between health plan 
(3.22, SD = 0.97) and PBM (3.42, SD = 0.70) representatives (t = - 1.008; df = 103; p = 
0.316) on whether long-term co-pay subsidy coupons improve likelihood of prescription 
refill. 
Hypothesis 6: There is no difference in the mean perception of Health Plan/PBM 
representatives toward short-term use co-pay subsidy coupon elimination by the 
predominant managed care organization. 
T-test for Hypothesis 6 
The T-test showed no significant difference in mean perception score between health plan 
(4.00, SD = 1.00) and PBM (3.85, SD = 1.04) representatives (t = 0.673; df = 103; p = 
0.503) on whether short-term co-pay subsidy coupons should be eliminated. 
Hypothesis 7: There is no difference in the mean perception of Health Plan/PBM 
representatives toward long-term use co-pay subsidy coupon elimination by the 
predominant managed care organization. 
T-test for Hypothesis 7 
 The T-test showed no significant difference in mean perception score between health 
plan (4.13, SD =1.00) and PBM (4.08, SD = 1.01) representatives (t = 0.218; df = 103; p 
= 0.791) toward long-term co-pay subsidy coupon elimination. 
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3.3.2 One-way ANOVA 
3.3.2.1 One-way ANOVA for Dependent Variables by Position in MCO 
A one-way ANOVA was used to compare the dependent variables (i.e., the mean 
perception score of MCO respondents) controlling for respondent’s position within the 
organization (IV2). Table 3.11 provides the descriptive statistics (i.e., mean, and standard 
deviation) of all the four groups i.e., executive officer; program manager; director; and 
pharmacist. This is followed with Table 3.12 which tests the difference in the mean 




Table 3.11 Mean Perception Scores of Dependent Variables by Different Positions 
within the MCO 
















 Mean  SD Mean   SD Mean   SD Mean   SD Mean   SD 
Co-pay subsidy coupon use 
encourages non-preferred 
brand-name drug 




4.56   0.73 4.54   0.51 4.41   0.78 4.57    0.51 4.48    0.68 
Short-term use co-pay 
subsidy coupons increase 
drug cost to plan sponsors 
 
4.78   0.44 4.42   0.76 4.41   0.78 4.29   0.83 4.43   0.77 
Long-term use co-pay 
subsidy coupons increase 
drug cost to plan sponsors 
 
4.78   0.44 4.54    0.76 4.61   0.67 4.43  0.85 4.58  0.70 
Co-pay subsidy coupon use 
improve likelihood of first 
prescription being filled 
 
3.33   1.12 3.46    0.76 3.36    0.95 3.71    0.83 3.43    0.90 
Co-pay subsidy coupon use 
improve likelihood of refill 3.33   1.00 3.46    0.70 3.09    0.98 3.57    0.85 3.27    0.91 
Short-term use co-pay 
subsidy coupons should be 
eliminated 
 
4.44   1.01 3.69    1.05 4.09    0.90 3.64    1.22 3.96    1.00 
Long-term use co-pay 
subsidy coupons should be 
eliminated 
4.33   1.12 3.81  1.17 4.29  0.85 3.86  1.09 4.11    1.00 





Table 3.12 ANOVA for Dependent Variables by Different Positions within MCO  
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Interpretation of Results of One-way ANOVA 
This section summarizes the hypothesis and results of one-way ANOVA analyses 
for each hypothesis. The independent variable is position within organization. 
Hypothesis 1: There is no difference in the mean perception score of Health Plan/PBM 
representatives toward whether co-pay subsidy coupons encourage patients to use non-
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preferred brand-name drugs instead of preferred brand-name drugs by the position in the 
organization. 
One-way ANOVA for Hypothesis 1 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
whether co-pay subsidy coupons encourage patients to use non-preferred brand-name 
drugs instead of preferred brand-name drugs) among executive officer (4.56 ± 0.73), 
program manager (4.54 ± 0.51), director (4.41 ± 0.78), and pharmacist (4.57 ± 0.51) 
groups; (F = 0.371; df = 3, 101; p = 0.774). 
Hypothesis 2: There is no difference in the mean perception score of Health Plan/PBM 
representatives regarding whether short-term use co-pay subsidy coupons increase drug 
costs to plan sponsor by the position in the organization. 
One-way ANOVA for Hypothesis 2 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
whether short-term use co-pay subsidy coupons increase drug cost to plan sponsor) 
among executive officer (4.78 ± 0.44), program manager (4.42 ± 0.76), director (4.41 ± 
0.78), and pharmacist (4.29 ± 0.83) groups; (F = 0.809; df = 3,101; p = 0.492). 
Hypothesis 3: There is no difference in the mean perception score of Health Plan/PBM 
representatives regarding whether long-term use co-pay subsidy coupons increase drug 
costs to plan sponsor by the position in the organization. 
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One-way ANOVA for Hypothesis 3 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
whether long-term use co-pay subsidy coupons increase drug cost to plan sponsor) among 
executive officer (4.78 ± 0.44), program manager (4.54 ± 0.76), director (4.61 ± 0.67), 
and pharmacist (4.43±0.85) groups; (F = 0.503; df = 3,101; p = 0.681). 
Hypothesis 4: There is no difference in the mean perception of Health Plan/PBM 
representatives in regard to co-pay subsidy coupons improving likelihood of first 
prescription being filled by the position in the organization. 
One-way ANOVA for Hypothesis 4 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
whether use of co-pay subsidy coupons improves likelihood of first prescription being 
filled) among executive officer (3.33 ± 1.12), program manager (3.46 ± 0.76), director 
(3.36 ± 0.95), and pharmacist (3.71 ± 0.83) groups; (F = 0.602; df = 3,100; p = 0.615). 
Hypothesis 5: There is no difference in the mean perception of Health Plan/PBM 
representatives in regard to co-pay subsidy coupons improving likelihood of prescription 
refill by the position in the organization. 
One-way ANOVA for Hypothesis 5 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
whether use of co-pay subsidy coupons improves likelihood of prescription refill) among 
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executive officer (3.33 ± 1.00), program manager (3.46 ± 0.70), director (3.09 ± 0.98), 
and pharmacist (3.57 ± 0.85) groups; (F = 1.670; df = 3,101; p = 0.178). 
Hypothesis 6: There is no difference in the mean perception of Health Plan/PBM 
representatives toward short-term use co-pay subsidy coupon elimination by the position 
in the organization. 
One-way ANOVA for Hypothesis 6 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
short-term use co-pay subsidy coupons should be eliminated) among executive officer 
(4.44 ± 1.01), program manager (3.69 ± 1.05), director (4.09 ± 0.90), and pharmacist 
(3.64 ± 1.22) groups; (F = 2.138; df = 3,101; p = 0.100). 
Hypothesis 7: There is no difference in the mean perception of Health Plan/PBM 
representatives toward long-term use co-pay subsidy coupon elimination by the position 
in the organization. 
One-way ANOVA for Hypothesis 7 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
long-term co-pay subsidy coupons should be eliminated) among executive officer (4.33 ± 
1.12), program manager (3.81 ± 1.17), director (4.29 ± 0.85), and pharmacist (3.86 ± 
1.09) groups; (F = 1.849; df = 3,101; p = 0.143). 
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3.3.2.2 One-way ANOVA for Dependent Variables by Number of Beneficiaries 
Enrolled in MCO 
Another one-way ANOVA was performed to compare the perception score by the 
independent variable number of beneficiaries enrolled (IV4). Table 3.13 provides the 
descriptive statistics (i.e., mean, standard deviation) of the four groups (i.e., less than 1 
million lives; 1,000,000 – 4,999,999; 5,000,000 – 9,999,999; and 10 million and above). 
This is followed with Table 3.14 which tests the difference in the mean perception scores 




Table 3.13 ANOVA Comparison of Mean Perception Score by Number of 
Beneficiaries Enrolled by MCO 
Dependent Variable Enrollment Statusa Totalb 



















 Mean  SD Mean   SD Mean   SD Mean   SD Mean   SD 
Co-pay subsidy coupon 
use encourages non-
preferred brand-name 
drug utilization instead of 
preferred brand-name 
drugs 
4.42    0.67 4.58     0.50 4.56    0.53  4.44    0.87 4.47    0.68 
Short-term use co-pay 
subsidy coupons increase 
the drug cost to plan 
sponsors 
4.50    0.76 4.32    0.88 4.44    0.73 4.40    0.65 4.44    0.75 
Long-term use co-pay 
subsidy coupons increase 
the drug cost to plan 
sponsors 
4.62    0.72 4.53    0.77 4.67    0.50 4.56    0.65 4.59    0.69 
Co-pay subsidy coupon 
use improve likelihood of 
first prescription being 
filled# 
3.40    0.88 3.44    0.86 3.67    1.22 3.36    0.86 3.42   0.89 
Co-pay subsidy coupon 
use improve likelihood of 
refill 
3.28    0.97 3.32   0.88 3.44    1.13 3.12   0.78 
 
3.26   0.91 
 
Short-term use co-pay 
subsidy coupons should 
be eliminated 
3.98    1.02 4.16   0.83 3.89    1.17 3.92    1.03 3.99    0.99 
Long-term use co-pay 
subsidy coupons should 
be eliminated 
4.10    1.02 4.47   0.61 3.89    1.17 4.08   1.07 4.15    0.98 
Dependent variables were measured on 5-point Likert scale ranging 1 to 5 (1 = ‘Strongly Disagree’ and 5 = 
‘Strongly Agree’) 
aNumber of beneficiaries enrolled by the MCO 
bTotal Number of Respondents Combined 
cmissing responses – 2 
# For group with organization enrollment of 1,000,000 to 4,999,999 ; N=18 
SD – Standard Deviation 
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Table 3.14 ANOVA Comparison of Dependent Variables by Number of 
Beneficiaries Enrolled by MCO  





Co-pay subsidy coupon use 
encourages non-preferred 
brand-name drug utilization 
instead of preferred brand-
name drugs 
 
   Between 
   Within 










Short-term use co-pay 
subsidy coupons increase 
drug cost to plan sponsor 
 
   Between 
   Within 










Long-term use co-pay 
subsidy coupons increase 
drug cost to plan sponsors 
 
   Between 
   Within 










Co-pay subsidy coupon use 
improve likelihood of first 
prescription being filled# 
 
   Between 
   Within 










Co-pay subsidy coupon use 
improve likelihood of refill 
   Between 
   Within 










Short-term use co-pay 
subsidy coupons should be 
eliminated 
   Between 
   Within 










Long-term use co-pay 
subsidy coupons should be 
eliminated 
   Between 
   Within 










# For group with enrollment 1,000,000 to 4,999,999 ; N=18 
 
Interpretation of Results of One-way ANOVA 
Each hypothesis and the results of the one-way ANOVA are summarized below: 
Hypothesis 1: There is no difference in the mean perception score of Health Plan/PBM 
representatives toward whether co-pay subsidy coupons encourage patients to use non-
preferred brand-name drugs instead of preferred brand-name drugs by the number of 
beneficiaries enrolled. 
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One-way ANOVA for Hypothesis 1 
A one-way ANOVA showed no significant differences in mean (SD) perception score 
(i.e., whether co-pay subsidy coupons encourage patients to use non-preferred brand-
name drugs instead of preferred brand-name drugs) among groups with number of 
beneficiaries enrolled less than 1 million (4.42 ± 0.67); 1,000,000 – 4,999,999 (4.58 ± 
0.50); 5,000,000 – 9,999,999 (4.56 ± 0.53); and 10 million and above (4.44 ± 0.87) 
(F=0.306; df= 3, 99; p = 0.821). 
Hypothesis 2: There is no difference in the mean perception score of Health Plan/PBM 
representatives regarding whether short-term use co-pay subsidy coupons increase drug 
costs to plan sponsor by the number of beneficiaries enrolled. 
One-way ANOVA for Hypothesis 2 
A one-way ANOVA showed no significant differences in mean (SD) perception score 
(i.e., whether short-term use co-pay subsidy coupons increase drug cost to plan sponsor) 
among groups with number of beneficiaries enrolled less than 1 million (4.50 ± 0.76); 
1,000,000 – 4,999,999 (4.32 ± 0.88); 5,000,000 – 9,999,999 (4.44 ± 0.73); and 10 million 
and above (4.40 ± 0.65) (F=0.298; df= 3, 99; p = 0.827). 
Hypothesis 3: There is no difference in the mean perception score of Health Plan/PBM 
representatives regarding whether long-term use co-pay subsidy coupons increase drug 
costs to plan sponsor by the number of beneficiaries enrolled. 
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One-way ANOVA for Hypothesis 3 
A one-way ANOVA showed no significant differences in mean (SD) perception score 
(i.e., whether long-term use co-pay subsidy coupons increase drug cost to plan sponsor) 
among groups with number of beneficiaries enrolled less than 1 million (4.62 ± 0.72); 
1,000,000 – 4,999,999 (4.53 ± 0.77); 5,000,000 – 9,999,999 (4.67 ± 0.50); and 10 million 
and above (4.56 ± 0.65) (F=0.134; df= 3, 99; p = 0.940). 
Hypothesis 4: There is no difference in the mean perception of Health Plan/PBM 
representatives in regard to co-pay subsidy coupons improving likelihood of first 
prescription being filled by the number of beneficiaries enrolled. 
One-way ANOVA for Hypothesis 4 
A one-way ANOVA showed no significant differences in mean (SD) perception score 
(i.e., whether use of co-pay subsidy coupons improves likelihood of first prescription 
being filled) among groups with number of beneficiaries enrolled less than 1 million 
(3.40 ± 0.88); 1,000,000 – 4,999,999 (3.44 ± 0.86); 5,000,000 – 9,999,999 (3.67 ± 1.22); 
and 10 million and above (3.36 ± 0.86) (F=0.272; df= 3, 98; p = 0.845). 
Hypothesis 5: There is no difference in the mean perception of Health Plan/PBM 
representatives in regard to co-pay subsidy coupons improving likelihood of prescription 
refill by the number of beneficiaries enrolled. 
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One-way ANOVA for Hypothesis 5 
A one-way ANOVA showed no significant differences in mean (SD) perception score 
(i.e., whether use of co-pay subsidy coupons improves likelihood prescription refill) 
among groups with number of beneficiaries enrolled less than 1 million (3.28 ± 0.97); 
1,000,000 – 4,999,999 (3.32 ± 0.88); 5,000,000 – 9,999,999 (3.44 ± 1.13); and 10 million 
and above (3.12 ± 0.78) (F=0.339; df= 3, 99; p = 0.797). 
Hypothesis 6: There is no difference in the mean perception of Health Plan/PBM 
representatives toward short-term use co-pay subsidy coupon elimination by the number 
of beneficiaries enrolled. 
One-way ANOVA for Hypothesis 6 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
short-term use co-pay subsidy coupons should be eliminated) among groups with number 
of beneficiaries enrolled less than 1 million (3.98 ± 1.02); 1,000,000 – 4,999,999 (4.16 ± 
0.83); 5,000,000 – 9,999,999 (3.89 ± 1.17); and 10 million and above (3.92 ± 1.03) 
(F=0.249; df = 3, 99; p = 0.862). 
Hypothesis 7: There is no difference in the mean perception of Health Plan/PBM 
representatives toward long-term use co-pay subsidy coupon elimination by the number 
of beneficiaries enrolled. 
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One-way ANOVA for Hypothesis 7 
One-way ANOVA showed no significant differences in mean (SD) perception score (i.e., 
long-term co-pay subsidy coupons should be eliminated) among groups with number of 
beneficiaries enrolled less than 1 million (4.10 ± 1.02); 1,000,000 – 4,999,999 (4.47 ± 
0.61); 5,000,000 – 9,999,999 (3.89 ± 1.17); and 10 million and above (4.08 ± 1.07) 
(F=0.980; df= 3, 99; p = 0.405). 
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3.3.3 Summary of Results of Hypotheses Testing 
The following table presents a summary of results of hypotheses testing.  
Table 3.15 Summary of Results of Hypotheses Testing 
Hypothesis Results* 
H01: There is no difference in the mean perception score of 
Health Plan/PBM representatives toward whether co-pay 
subsidy coupons encourage patients to use non-preferred 
brand-name drugs instead of preferred brand-name drugs by 
the predominant managed care organization, the position in 






H02: There is no difference in the mean perception score of 
Health Plan/PBM representatives regarding whether short-
term use co-pay subsidy coupons increase drug costs to plan 
sponsor by the predominant managed care organization, the 








H03: There is no difference in the mean perception score of 
Health Plan/PBM representatives regarding whether long-
term use co-pay subsidy coupons increase drug costs to plan 
sponsor by the predominant managed care organization, the 




H04: There is no difference in the mean perception of Health 
Plan/PBM representatives in regard to co-pay subsidy 
coupons improving likelihood of first prescription being 
filled by the predominant managed organization, the position 
in the organization, and number of beneficiaries. 
 
Not Rejected 




Table 3.15 Summary of Results of Hypotheses Testing (continued) 
Hypothesis Results* 
H05: There is no difference in the mean perception of Health 
Plan/PBM representatives in regard to co-pay subsidy 
coupons improving likelihood of prescription refill by the 
predominant managed organization, the position in the 





H06: There is no difference in the mean perception of Health 
Plan/PBM representatives toward short-term use co-pay 
subsidy coupon elimination by the predominant managed 
care organization, the position in the organization, and 







H07: There is no difference in the mean perception of Health 
Plan/PBM representatives toward long-term use co-pay 
subsidy coupon elimination by the predominant managed 
care organization, the position in the organization, and 
number of beneficiaries. 
Not Rejected 







 Chapter Four: Discussion 
This chapter provides a summary of the major findings of the study and will 
discuss the significance or implications of these findings with respect to the literature. In 
addition, the chapter will assess limitations of this study and give directions for future 
research. 
4.1 REVIEW OF RESEARCH QUESTIONS 
One of the many roles for MCOs is increasing value and use of pharmaceuticals 
by making drugs affordable, accessible and improving their use while maximizing 
positive patient outcomes. In order to achieve this goal, along with managing costs for 
plan sponsors, MCOs have implemented certain strategies. One of MCOs’ several 
strategies is establishing drug formularies and promoting generic products. Most drug 
formularies have a preferred drug list and tiered cost structure with generic drugs placed 
at lowest tier. The objective is to make appropriate drugs accessible to all members, while 
allowing access of expensive medical alternatives for certain members.  
In recent times, coupon/voucher offers have been used for: 1). launching new 
drugs; 2) brand-name drugs which are approaching patent expiration; 3) enhancing 
competition between two or more brand-name drugs; and 4) lifestyle drugs and specialty 
drugs. The coupon offers are widely seen in magazine ads, newspapers, or are offered at 
physician offices. In addition, internet search results direct an information seeker to a 
manufacturer-sponsored web homepage or to a drug coupons website that has an 
alphabetical listing of discounted prescription drugs. Such promotions are short-term for 
introducing products or may last for a year (long-term). An important component of 
brand-name drug coupon promotion is that it waives or subsidizes out-of-pocket costs 
(co-pays) of patients enrolled in health plans. The patient portion of the drug costs are 
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covered by drug companies promoting their product using coupon offers while the 
remainder of costs are covered by plan sponsors. While MCOs are offering incentives to 
their members to use affordable available generic drugs, pharmaceutical companies are 
increasing access to their brand-name drugs by offering co-pay subsidies. Little is known 
in the literature about the perceptions MCO representatives have toward brand-name drug 
coupon programs that subsidize their plan members’ costs. 
This study was conducted on a sample of MCO representatives (i.e., health plan 
managers and pharmacy benefit managers). The purpose was to determine the 
perceptions of MCO representatives toward co-pay subsidy coupons. Specific objectives 
were to determine their perceptions regarding:  whether co-pay subsidy coupons led to 
increase in non-preferred brand-name drugs instead of preferred brand-name drugs; 
whether coupons improved patient adherence; whether short-term use and long-term use 
coupons increased plan sponsor costs; and if both these type of coupons should be 
eliminated. In addition, the objective of this study was to find out if MCOs monitored 
changes in coupon activity, monitored costs incurred to their organization due to 
coupons, and if they discussed ways to counteract coupon offers. 
4.2 STUDY FINDINGS 
MCO Characteristics 
Of the 105 respondents who answered the survey, 79 (75.2%) were health plan 
managers and 26 (24.8%) were PBM representatives.  A total of 95.2% of the 
respondents were licensed pharmacists. A total of 56 (53.3%) were directors of 
pharmacy, formulary or clinical operations. Slightly less than half (46.7%) of the 
respondents had beneficiary enrollment of less than 1 million.  
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All of the MCO respondents who answered the survey were aware of the use of 
co-pay subsidy for brand-name prescription drugs. According to MCO respondents, the 
most widely used marketing approaches for coupon distribution were through physician 
offices 90 (85.7%), followed by internet offers 74 (70.5%), and magazine coupons 60 
(57.1%). A majority of MCO respondents, 91 (86.7%) believed that co-pay subsidy 
coupons offered by pharmaceutical manufacturers had increased in 2011 as compared to 
2010. This finding was highlighted in the recent article published in the Wall Street 
Journal that notes there were 310 co-pay card programs in 2011 - a rise of 260% over the 
previous two years.58 Forty seven (44.7%) respondents had an opinion that 10 or more of 
the top 20 brand-name drugs used coupons for promotion. This finding is consistent with 
the Weppner et al. study that notes more than 30 out of 50 most prescribed brand-name 
drugs have internet offers in term of coupons or vouchers.59  
Coupon Monitoring Activities 
MCO respondents were asked if their organization monitored use of 
coupons/vouchers by their plan members. Seventy-two (68.6%) respondents answered 
‘No.’ When asked if their organization contracted with another organization to monitor 
use of brand-name coupons/vouchers, 95 (90.5%) respondents answered ‘No.’ With 
respect to monitoring costs incurred to their organization due to coupons, 71 (67.6%) 
answered ‘No’ they did not monitor costs. This study found that a low proportion of 
MCOs monitored use (22.9%, N = 24) and costs (21.9%, N = 23) incurred due to 
coupons. These findings suggest that monitoring coupons may involve additional time 
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consuming effort on part of MCOs. Furthermore, data received from pharmacies may not 
track if co-pay was made by the patient or the drug manufacturer.  
Perception Regarding Impact of Coupons on Brand-name Drug Utilization 
MCO representatives perceived that the utilization of generic drugs was affected 
by co-pay subsidy coupons. Fifty-four (51.4%) respondents ‘agreed’ that patients were 
more likely to shift from generic to brand-name drugs on receiving co-pay subsidy 
coupons. Fifty-one (49%) respondents ‘strongly agreed’ that brand-name drug utilization 
increased instead of generic drugs. The hypotheses testing showed no significant 
difference in perception of MCO representatives toward whether co-pay subsidy coupons 
encouraged utilization of non-preferred brand-name drugs over preferred brand drugs by 
predominant MCO, position in the MCO, and number of beneficiaries enrolled. In this 
study, a majority of MCO respondents 58 (55.2%) ‘strongly agreed’ whereas 42 (40%) 
‘agreed’ that co-pay subsidy coupons encouraged use of non-preferred brand-name drugs 
instead of preferred brand-name drugs. The literature suggests that MCOs use three or 
more tiers in drug formularies. These are incentive-based formularies that provide the 
lowest co-pays for generic drugs, followed by ‘select’ brand-name drugs called preferred 
brands and the top tiers consists of non-preferred drugs which have higher co-pays. 
Studies suggest that adding tiers for non-preferred drugs lowers costs paid by health 
plans.60 A possible explanation for this is that plan members choose equivalent available 
generic drugs or preferred brands instead of costlier alternatives. However, with co-pay 
subsidy coupons waiving out-of-pocket costs on non-preferred or non-formulary brand-
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name drugs for plan members, there is no incentive to choose generic or preferred brand-
name drugs.  
Perception toward Brand Loyalty and Costs of Co-pay Subsidy Coupons (Short-
term use Versus Long-term use) 
 For the item, ‘A majority of patients who take advantage of short-term use co-pay 
subsidy coupons become regular users of brand-name drugs.’ it is interesting to note that 
48 (45.7%) ‘agreed’, 13 (12.4%) ‘strongly agreed’ , while 18 (17.1%) ‘disagreed’ with 
the statement. Short-term use coupons are typically distributed for trial purposes with 
limited use. Previous studies in consumer research suggest that short-term coupon 
promotions draw deal-prone users who are less likely to continue using products.61 
Similar findings were observed for the statement, ‘Short-term use co-pay subsidy 
coupons build brand loyalty toward brand-name prescription drugs.’; 47 (45.2%) 
‘agreed’ while 14 (13.5%) ‘disagreed’. These findings are not consistent with previous 
consumer behavior studies that suggest deal-prone consumers revert back to their original 
brands when deals are withdrawn, that is, short-term deal prone shoppers are not brand 
loyal.61-62 A possible explanation could be that unlike consumer products, even short-
term coupon promotion for brand-name prescription drugs are very effective in getting 
patients to use drugs for a long time. 
The findings for the statement, ‘a majority of patients who take advantage of  
long-term use co-pay subsidy coupons become regular users of brand-name drug.’ were 
41 (39.4%) respondents indicating ‘strongly agreed’,  48 (46.2%) ‘agreed’ while 10 
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(9.6%) respondents had ‘neutral’ perception and a mean perception score of 4.19 (0.84).  
With respect to long-term use coupons, 54 (51.4%) ‘agreed’ while 37 (35.2%) ‘strongly 
agreed’ that long-term use co-pay subsidy coupons build brand-loyalty. The mean 
perception score was 4.17 (0.77). Overall, MCO respondents perceived that patient using 
coupons for a long period of time as in case of co-pay cards that were offered for refills 
up to a year may become regular users and brand loyals. 
MCO representatives perceived that both short-term use and long term use co-pay 
subsidy coupons increased drug cost to plan sponsors. Hypotheses testing showed no 
significant difference in mean perception score of MCO representatives toward whether 
short-term and long-term co-pay subsidy coupons increased drug cost to plan sponsors by 
predominant MCO, position in the MCO, and number of beneficiaries enrolled.  Of the 
105 MCO respondents, 60 (57.1%) respondents ‘strongly agreed’ that plan sponsor’s cost 
increased due to short-term use coupons and 72 (68.6%) respondents ‘strongly agreed’ 
that plan sponsor’s cost increased due to long-term use coupons. The mean perception 
scores on whether short-term use and long-term use co-pay subsidy coupons increased 
drug costs to plan sponsor were 4.43 (0.76) and 4.58 (0.70), respectively. A possible 
explanation for this finding could be that MCOs try to effectively utilize health care 
resources by making appropriate drugs available to plan members. However, in the face 
of escalating drug prices, use of co-pay subsidy coupon promotions directly affects their 
cost containment efforts. Evidence suggests that the increasing coupon promotions may 
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inflate the prescription drug costs.63  As more patients use coupons that eliminate their 
co-pays, it is apparent that MCOs perceive co-pay subsidy coupons increase plan costs. 
Perception Regarding Impact of Coupons on Adherence 
Drug manufacturers claim that coupons for brand-name drugs are a part of 
patient-directed programs.64 These discount programs enable patients to start a new drug 
or continue with an existing drug.65 Co-pay subsidy coupons reduce the financial burden 
of patients by decreasing their out-of-pocket costs. Studies have reported that patient-
directed programs such as LoyaltyScript show higher persistence rates among patients 
enrolled in the program.66 In this study, an attempt was made to investigate if MCO 
respondents perceived that co-pay subsidy coupons increased primary adherence (i.e., 
rate at which patients filled first prescriptions) and persistence (i.e., rate of refill).67  
Hypotheses testing for MCO representatives’ perception toward items, ‘Co-pay 
subsidy coupons improve the likelihood that patients will get their first prescription 
filled,’ and ‘Co-pay subsidy coupons improve the likelihood of refill,’ showed that there 
was no significant differences in the mean perception scores of MCO respondents by 
predominant MCO, position in the MCO, and number of beneficiaries enrolled.   For the 
item, ‘Co-pay subsidy coupons improve the likelihood that patients will get their first 
prescription filled,’ the results show mixed responses with the frequency of responses 
almost tied with 40 (38.1%) MCO respondents indicating a ‘neutral’ response and 39 
(37.1%) indicating ‘agreed.’ There were 12 (11.5%) respondents who ‘disagreed’ while 2 
(1.9%) respondents ‘strongly disagreed’ (Table 3.2). The mean perception score was 3.43 
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(0.90). Previous studies suggest that an increase in prescription drug co-pays decreases 
medication adherence.68-69 Furthermore, drug coupons are incentives that are more likely 
to draw consumers toward filling prescriptions. Of the 105 respondents, 14 disagreed that 
co-pay subsidy coupons will encourage likelihood of first prescription fills. These 
findings contradict the results pertaining to earlier statements in this survey (i.e., when 
asked if patients using coupons become regular users or brand-loyals for long-term use 
coupons, greater proportion of MCO respondent agreed. The mean perceptions scores are 
4.19 (0.84) and 4.17 (0.78), respectively.  However, when asked if co-pay subsidy 
coupons improve likelihood that patients will obtain refill prescriptions, there is relatively 
less agreement among MCO respondents and a dip in the mean perception score to 3.27 
(0.91). .  
In the case of MCO respondents’ perceptions toward co-pay subsidy coupons 
improving the likelihood of prescription refill, 20 (19.0%) ‘disagreed’ while the number 
of MCO respondents who indicated ‘neutral’ were 38 (36.2%), the same as those who 
‘agreed.’  A mean perception score of 3.27 (0.91) was observed. With coupons 
distributed repeatedly for longer periods (long-term use coupons), it is expected that 
patients are more likely to use them repeatedly for refills. Of the 105 respondents, 60 
respondents did not believe that coupons improve likelihood of prescription refills.  
While increasing promotion of their prescription drugs by using co-pay subsidy 
coupons, pharmaceutical companies emphasize that waived co-payments will help 
overcome non-adherence (i.e., medication discontinuation) due to high drug costs. It is 
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documented that consumers are sensitive toward drug co-pay increases and that 
increasing co-pays affects adherence. Waived co-pays on prescription drugs through 
coupons provide an incentive for consumers to try new expensive drug alternatives. This 
is increasing costs for plan sponsors. While MCOs want to eliminate coupon promotion, 
they find this beyond their control. Hence, they may be inclined to report that coupons do 
not increase adherence or persistence. 
Perception Regarding Impact of Coupons on Formulary Structure and Elimination 
of Coupon Offers 
MCO respondents had a unanimous agreement that co-pay subsidy coupons were 
disrupting the tiered formulary structure. Of the 105 respondents who answered the 
survey, 78 (74.3%) respondents ‘strongly agreed’ that co-pay subsidy coupons 
undermined tiered formulary structure. This is because co-pay subsidy coupons are 
mostly available for non-preferred drugs. These non-preferred drugs are placed in higher 
cost tiers to provide an incentive to use generics and preferred brand-name drugs. When 
respondents were asked to estimate the percentage increase in utilization of non-preferred 
brand-name drugs due to co-pay subsidy coupons, 79 (75.2%) indicated ‘don’t know.’ 
In terms of co-pay subsidy coupon elimination, hypotheses testing showed that 
there were no significant differences in mean perception score of MCO representatives 
toward both short-term and long-term co-pay subsidy coupon elimination by predominant 
MCO, position in the MCO, and number of beneficiaries enrolled. Forty-two (40%) 
respondents ‘strongly agreed’ that short-term use coupons should be eliminated whereas 
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49 (46.7%) respondents ‘strongly agreed’ that long-term use coupons should be 
eliminated. The mean perception scores were 3.96 (1.00) toward short-term coupon 
elimination and 4.11 (1.00) toward long-term coupon elimination. In particular, MCO 
representatives were sensitive to co-pay subsidy coupon promotion with a majority 
perceiving that coupons should be banned. However, few respondents disagreed or had 
neutral opinions (Table 3.2) toward both short-term use and long-term use coupon 
elimination. A possible explanation could be that MCO representatives may welcome co-
pay subsidy coupons for expensive specialty drugs that are used to treat complex medical 
conditions such as cancer, inflammatory condition, multiple sclerosis, and other complex 
disorders. An article in Drug Benefit News points out that although health plans should 
adopt strategies to counteract some prescription co-pay subsidy coupons, they should 
partner with pharmaceutical companies on costly treatments that use specialty drugs. 70  
A majority 65.7%, N = 69) of respondents indicated that their organization 
discussed ways to discourage co-pay subsidy coupon use within past year. When MCO 
respondents were asked to specify ways in which coupons can be discouraged, a majority 
favored using a step therapy approach. In addition, respondents indicated that MCOs 
should omit coverage for drugs with coupons, start their own coupon incentive programs 
for generic and preferred drugs, or use mandatory mail-order service. 
4.3 STUDY LIMITATIONS 
Like any research project this study has limitations. This study cannot be 
generalized due to the fact that it used a convenience sample and the sample size was 
 84 
relatively small. This study used a sample from the AMCP directory and thus, it may be 
possible that AMCP members may have different perspectives than the general MCO 
population. 
The study assessed perceptions of MCO representatives toward co-pay subsidy 
coupons and perceptions may evolve or change with time. Hence, we are not assured that 
MCO representatives may have the same views today as they did when the study was 
conducted. Plus, as with all questionnaire studies, there may be differences in interpreting 
the items or questions.  
The study response rate was low (i.e., 13.68%) and a non-response bias was not 
accounted for in this study. It is possible that non-respondent MCO representatives will 
have different perceptions toward co-pay subsidy coupons than those who did respond. It 
is possible that some organizations may prohibit access to survey links or prohibit their 
employees from participation in surveys due to corporate survey policies. 
Finally, the survey was self administered (i.e., all the responses were self 
reported).   
4.4 CONCLUSION  
Overall, the findings of this study demonstrate that MCO representatives 
perceived co-pay subsidy coupons for brand-name prescription drugs do present a 
problem for managed care organizations. The results show that many MCO 
representatives perceived that co-pay subsidy coupons increased brand-name drug 
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utilization, undermined tiered formulary structure, and increased costs to plan sponsors. 
The results were not conclusive in regard to co-pay subsidy coupons improving patient 
adherence and persistence. MCO representatives considered short-term use coupons as 
less problematic than long-term use coupons. This could be because long-term use 
coupons may increase brand-loyalty and brand drug use. A majority of respondents 
agreed that co-pay subsidy coupons should be eliminated. These results are in line with 
the anticipated responses given that MCOs are bound to be sensitive toward 
coupons/vouchers that directly impact their cost containment strategies. It is “all about 
access;” as plan sponsors switch their plan members to tiered formularies that restrict 
access to expensive drugs, brand-name drug manufacturers are promoting their products 
to help patients get access to blockbuster moieties. 
4.5 DIRECTIONS FOR FUTURE RESEARCH 
This study uses MCOs’ perspectives on use of co-pay subsidy coupons. It would 
be interesting to investigate the consumers/plan members’ perspective toward co-pay 
subsidy coupon use. In addition, it would be interesting to assess consumers’ perceptions 
if health plans decide to ban coupon use or implement strategies to counteract coupons. 
Furthermore, the literature is lacking in studies that explore effects of coupon use on 
medication persistence. Another unexplored area from MCO’s perspective could be 








A Web-Based Survey to Assess the Perceptions of Managed Care Organization 
Representatives Regarding Use of Co-pay Subsidy Coupons for Brand-name 
Prescription Drugs 
 
The purpose of this survey is to assess your perceptions about co-pay subsidy coupons or 
vouchers. Since you work for a health plan or a pharmacy benefit management firm, you 
have been identified as a candidate for our study. 
Co-pay subsidy coupons and vouchers are offered by pharmaceutical manufacturers for 
certain brand-name prescription drugs. For the purpose of this survey, a co-pay subsidy 
coupon will be defined as a promotional financial incentive such as a coupon, voucher, or 
a co-pay card (also known as a loyalty card) that waives co-payment partially or 
completely on a brand-name prescription drug. 
 
I.  In this section, we would like to know about your experiences with co-pay subsidy 
coupons. 
Please check the appropriate box that corresponds with your answer to the questions 
below. 
1. Before you received this survey, were you aware that co-pay subsidy coupons 
are being offered by some pharmaceutical manufacturers? 
 Yes (Please continue with question 2)   
 No (Please skip to Section III) 
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2. Listed below are marketing approaches for distributing prescription drug co-pay 
subsidy coupons. (In your opinion, please rank the three most widely used 
options using the numbers 1 through 3 with “1” being most widely used, “2” 




_____Direct mail to consumer 
_____Pharmacies 
_____Physicians 
_____Other ___________________ (Please specify and rank) 
 
3. Do you believe that in the past year the number of co-pay subsidy coupons 
offered by pharmaceutical manufacturers has increased, decreased, or stayed 
about the same as in the previous year? 
 Increased   
 Decreased  
 Stayed about the same  
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4. In your opinion, approximately how many of the top 20 brand-name prescription 





 10 or more  
 Don’t know 
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5.  Does your organization monitor coupon/voucher use for brand-name 
prescription drugs?  
 Yes 
 No 
 Don’t know 
 
6. Does your organization contract with another organization to monitor the use 
of coupons for brand-name prescription drugs?   
 Yes 
 No 
 Don’t know 
 
7. Does your organization monitor costs to your organization due to 
coupon/voucher use for brand-name prescription drugs? 
 Yes 
 No 





II. In this section, we would like to know your perceptions regarding whether 
the use of co-pay subsidy coupons has an impact on brand–name drug 
utilization, patient adherence, and costs. 
 
Note:  Some items refer to long-term or short-term use coupons. 
 
Long-term use coupons are defined as co-pay cards that can be used 
repeatedly over a year to get co-pay discounts on refills. (For example, co-pay 
cards used for cholesterol lowering drugs). 
 
Short-term use coupons are defined as co-pay cards that are distributed for 
trial offers and have a limit on usage (For example, co-pay cards used for 
dermatology products may be limited to 3 refills). 
 
8. Please check the appropriate circle indicating your level of agreement with 





Disagree Neutral Agree 
Strongly 
Agree 
a. Patients are more likely to 
shift from generic to brand-
name drugs when they 
receive co-pay subsidy 
coupons. 
 
     
b. Co-pay subsidy coupons 
increase utilization of brand-
name prescription drugs 
instead of generic drugs. 
 
     
c. Co-pay subsidy coupons are 
likely to encourage patients to 
use non-preferred brand-
name drugs instead of 
preferred brand-name drugs.  
 
     
d. The majority of patients who 
take advantage of short-term 
use co-pay subsidy coupons 
become regular users of 
brand-name drugs. 
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e. The majority of patients who 
take advantage of long-term 
use co-pay subsidy coupons 
become regular users of 
brand-name drugs. 
 
     
f. Short-term use co-pay 
subsidy coupons build brand 
loyalty toward brand-name 
prescription drugs. 
 
     
g. Long-term use co-pay 
subsidy coupons build brand 
loyalty toward brand-name 
prescription drugs. 
 
     
h. Co-pay subsidy coupons 
undermine the tiered 
formulary structure. 
 
     
i. Short-term use co-pay 
subsidy coupons increase 












j. Long-term use co-pay 
subsidy coupons increase 
drug costs for plan sponsors. 
 
     
k. Co-pay subsidy coupons 
improve the likelihood that 
patients will get their first 





















l. Co-pay subsidy coupons 
improve the likelihood that 
patients will obtain refill 
prescriptions. 
 
     
m. Short-term use brand drug 
co-pay subsidy coupons 
should be eliminated. 




9. Please estimate the percentage increase in utilization of non-preferred brand-
name drugs for the past year due to co-pay subsidy coupons? 
___________ % 
 Don’t know 
 
n. Long-term use brand drug 
co-pay subsidy coupons 
should be eliminated. 
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10. During the past year, has your organization had discussion about ways in which 
co-pay subsidy coupons could be discouraged? 
 Yes  
 No  
 Don’t know 
 
11. In your opinion, please specify the ways in which the use of co-pay subsidy 
coupons could be discouraged? (Check all that apply) 
 Increase difference in cost sharing between generics and non-formulary drugs 
 Use a step therapy approach (defined as coverage of second-line therapy after 
trial with first-line therapy) 
 Use adherence rewards for generics 
 Don’t know 
 Other (Please 







III. This section will help gather some information about you. 
Please check the appropriate box that corresponds with your answer to the questions 
below. 
 
12. Which of the following best describes the predominant managed care 
organization where you work? 
  Health Plan  
 Pharmacy Benefit Manager (PBM)  
 Other (Please specify)______________________________ 
 




14. Which of the following best describes your position within the organization 
where you are employed? 
 
 Executive Officer (President/Vice President) 
 Program Manager (Clinical, Pharmacy)  
 Director (Clinical Operations, Formulary, Pharmacy)  
 Pharmacist (Staff, Senior) 








15. What is your organization’s approximate total enrollment? ( i.e., indicate the 
number of lives covered by your plans) 
 
 < 1,000,000 lives 
  1,000,000 – 4,999,999 lives 
 5,000,000 – 9,999,999 lives 
 ≥ 10 million lives 
 Don’t know 
 



















Pharmaceutical manufacturers have used coupons, vouchers, or co-pay cards also known 
as loyalty cards for promoting brand-name prescription drugs. These coupons or co-pay 
cards lower or waive patients’ out-of-pocket costs (co-payments). In other words, drug 
manufacturer’s pay for patient’s portion of prescription drug cost. A co-payment is cost-
sharing component of patients enrolled in health plan. Coupons or vouchers circumvent 
the higher co-payments implemented by managed care firms for expensive brand-name 
drugs. Until now, there is little documentation about the impact of such patient-directed 
prescription coupon incentives particularly for managed care organizations (MCOs). 
 
We, at the University of Texas at Austin are in the process of conducting a research study 
to determine perceptions of MCO representatives regarding the use of prescription drug 
coupons or vouchers. Since you work for a health plan or a pharmacy benefit 
management firm, you have been identified as a candidate for this study. Your views are 
important as they will provide a solution to improve communication between managed 
care organizations and pharmaceutical companies. 
  
We invite you to participate in this study by completing a short questionnaire. It will only 
take 5 to 7 minutes.  Your participation in this study is voluntary. At the bottom of this 
email is a link to the questionnaire. 
 
We hope that you will participate in the project by completing the questionnaire. All 
responses are anonymous and will be kept confidential.  No identifying information such 
as your name or identification of your organization will be collected and responses will 
not be linked to you. The results of the study will be reported in aggregate form. 
Participation in the study poses little to no risk to you. The return of your completed 
survey will represent your consent to participate in this study. To participate in the study 
please click on the link at the bottom of this email. To reiterate, no email addresses or 
names will be collected. 
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If you have any questions about this project, you may contact us at (512)-471-5607 or 
email Poorva Nemlekar at poorva@mail.utexas.edu or Dr. Marvin Shepherd at 
marvshepherd@mail.utexas.edu 
 
If you have questions or concerns about your rights as a research participant or 
complaints, please contact the University of Texas at Austin Institutional Review Board 
Chair Jody Jenson at irbchair@austin.utexas.edu or the Office of Research Support at 
orsc@uts.cc.utexas.edu. 
Thank you for your help in advance. We greatly appreciate your time and efforts in 
taking this survey. 
 




                                
Marvin Shepherd, Ph.D.    Poorva Nemlekar, B.Pharm 
Director 






Last week we sent you a request to participate in a survey study that is being conducted 
by researchers at the College of Pharmacy at the University of Austin at Texas. This 
study is being conducted to determine perceptions of Managed Care Organization (MCO) 
representatives toward the use of brand-name prescription drug coupons or vouchers.  
Pharmaceutical manufacturers have used coupons, vouchers, or co-pay cards for 
promoting brand-name prescription drugs. Coupons or vouchers circumvent the higher 
co-payments of expensive brand-name drugs. Until now, there is little documentation 
about the impact of such patient-directed prescription coupon incentives particularly for 
managed care organizations (MCOs) 
If you have already taken the survey, Thank You. If not, we ask you to provide your 
feedback. This survey questionnaire will only take 5 to 7 minutes for completion.  Your 
participation in this study is voluntary. At the bottom of this email is a link to the 
questionnaire. 
We hope that you will participate in the project by completing the questionnaire. All 
responses are anonymous and will be kept confidential.  No identifying information such 
as your name or identification of your organization will be collected and responses will 
not be linked to you. The results of the study will be reported in aggregate form. 
Participation in the study poses little to no risk to you. The return of your completed 
survey will represent your consent to participate in this study. To participate in the study, 
please click on the link at the bottom of this email. To reiterate, no email addresses or 
names will be collected. 
 
If you have any questions about this project, you may contact us at (512)-471-5607 or 
email Poorva Nemlekar at poorva@mail.utexas.edu or Dr. Marvin Shepherd at 
marvshepherd@mail.utexas.edu 
If you have questions or concerns about your rights as a research participant or 
complaints, please contact the University of Texas at Austin Institutional Review Board 
Chair Jody Jenson at irbchair@austin.utexas.edu or the Office of Research Support at 
orsc@uts.cc.utexas.edu. 
Please click on the following link or paste it on your web browser to take the survey: 
https://www.surveymonkey.com/s/RSRTPYT 
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Thank you in advanced for your time and effort in completing the survey. Your help is 
greatly appreciated. 
Sincerely, 
           
 
 
Marvin Shepherd, Ph.D.    Poorva Nemlekar, B.Pharm 
Director 








Approximately three weeks ago, we sent you a request to participate in a survey study 
that is being conducted by researchers at the College of Pharmacy at the University of 
Austin at Texas. This study is being conducted to determine perceptions of Managed 
Care Organization (MCO) representatives toward the use of brand-name prescription 
drug coupons or vouchers.  
If you have already taken the survey, Thank You. If not, we ask you to provide your 
feedback. This survey questionnaire will only take 5 to 7 minutes for completion.  Your 
participation in this study is voluntary. At the bottom of this email is a link to the 
questionnaire. 
We hope that you will participate in the project by completing the questionnaire. All 
responses are anonymous and will be kept confidential.  No identifying information such 
as your name or identification of your organization will be collected and responses will 
not be linked to you. The results of the study will be reported in aggregate form. 
Participation in the study poses little to no risk to you. The return of your completed 
survey will represent your consent to participate in this study. To participate in the study, 
please click on the link at the bottom of this email. To reiterate, no email addresses or 
names will be collected. 
 
If you have any questions about this project, you may contact us at (512)-471-5607 or 
email Poorva Nemlekar at poorva@mail.utexas.edu or Dr. Marvin Shepherd at 
marvshepherd@mail.utexas.edu 
If you have questions or concerns about your rights as a research participant or 
complaints, please contact the University of Texas at Austin Institutional Review Board 
Chair Jody Jenson at irbchair@austin.utexas.edu or the Office of Research Support at 
orsc@uts.cc.utexas.edu. 













     
Marvin Shepherd, Ph.D.    Poorva Nemlekar, B.Pharm 
Director 
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